Roskamp Institute Articles

February 14, 2012

News:KEY CLINICAL TRIAL OF ALZHEIMER’S DISEASE DRUG BEGINS IN EUROPE DRUG DISCOVERED BY ROSKAMP INSTITUTE RESEARCH

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 12:46 pm
Contact: Steve Klindt
Tel: Tel:941-752-2949 x 390
Email: Sklindt@roskampinstitute.net

KEY CLINICAL TRIAL OF ALZHEIMER’S DISEASE DRUG BEGINS IN EUROPE DRUG DISCOVERED BY ROSKAMP INSTITUTE RESEARCH
SARASOTA, FL (Feb. 14) –

A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute (www.rfdn.org) in Sarasota. More than 500 Alzheimer’s patients in nine European countries will participate in the phase III trial designed to study the effectiveness of the medication.

“We believe that Nilvadipine blocks the production of amyloid proteins linked to Alzheimer’s disease,” said Roskamp Institute President and CEO Michael Mullan, M.D., Ph.D., who along with Associate Director Fiona Crawford, Ph.D., and Daniel Paris Ph.D. led the team that developed the drug. “That means Nilvadipine is aimed at addressing the actual disease, and not just the symptoms.”

A consortium of medical teams from nine European countries is meeting in Ireland this week to plan the US$10 million multicenter study. Phase III studies are usually the last step in the regulatory process before a drug can move into clinical practice. The consortium, called NILVAD for Nilvadipine/Alzheimer’s Disease, will involve participants from Ireland, England, Hungary, Greece, France, Sweden, Germany, Italy and the Netherlands.

The 500 participants, who have mild to moderate cognitive impairments, will begin the double-blind study this fall. Each participant will be followed for 18 months to see if the drug produces a change in cognitive abilities.

“We won’t cure Alzheimer’ disease without clinical trials,” said Crawford, who added that major pharmaceutical companies have not been able to come up with an effective drug. “Currently, there are only eight interventions underway in phase III trial, and it’s a tremendous achievement for a small research institute like ours to be part of the process.”

Event: Journal Club ” Therapeutic hypothermia alters microRNA responses to traumatic brain injury in rats. “

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 12:43 pm

Zuchra Zakirova will be presenting the paper on Friday (2/17/2012) at 4:00 PM in Roskamp Institute.
Title:  ”Therapeutic hypothermia alters microRNA responses to traumatic brain injury in rats ”

Truettner J.S., Alonso O.F., Bramlett H.M., Dietrich W.D. “Therapeutic hypothermia alters microRNA responses to traumatic brain injury in rats”. J Cereb Blood Flow Metab. 2011 Sep;31(9):1897-907

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.
The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

February 7, 2012

Event: Journal Club ” Lipidomic profiling of brain phosphatidylcholines and sphingomyelins in mice with motor and anxiety-like features of GWI ”

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 12:46 pm

We will have a special presentation for Journal Club this Friday (2/10/2012) at 4pm at the Roskamp Institute. Instead of reviewing a journal article, this week’s presenter — Laila Abdullah — will be presenting results from her own research. The title of her presentation is “Lipidomic profiling of brain phosphatidylcholines and sphingomyelins in mice with motor and anxiety-like features of GWI.”
Title: ” Lipidomic profiling of brain phosphatidylcholines and sphingomyelins in mice with motor and anxiety-like features of GWI.”

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

January 30, 2012

Event: Journal Club ” Alzheimer’s disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. ”

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 2:03 pm

Benoit Mouzon will be presenting the paper on Friday (2/3/2012) at 4:00 PM in Roskamp Institute.
Title: “ Alzheimer’s disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging.”

Maarouf CL, Daugs ID, Kokjohn TA, Walker DG, Hunter JM, Kruchowsky JC, Woltjer R, Kaye J, Castaño EM, Sabbagh MN, Beach TG, Roher AE. Alzheimer’s disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One. 2011;6(11):e27291. Epub 2011 Nov 7.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.
The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

January 23, 2012

Event: Journal Club ” Directed Conversion of Alzheimer’s Disease Patient Skin Fibroblasts into Functional Neurons “

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 1:11 pm

Alex Bishop will be presenting the paper on Friday (1/13/2012) at 4:00 PM in Roskamp Institute.
Title: ” Directed Conversion of Alzheimer’s Disease Patient Skin Fibroblasts into Functional Neurons ”

Liang Qiang, Ryousuke Fujita, Toru Yamashita, Sergio Angulo, Herve Rhinn, David Rhee, Claudia Doege, Lily Chau, Laetitia Aubry, William B. Vanti et al. 2011. Directed Conversion of Alzheimer’s Disease Patient Skin Fibroblasts into Functional Neurons. Cell. 146(3) pp. 359 – 371.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

January 11, 2012

Event: Journal Club ” Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer’s NFTs ”

Robert Pelot will be presenting the paper on Friday (1/13/2012) at 4:00 PM in Roskamp Institute.

Title: ” Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer’s NFTs ”

Rudrabhatla P, Jaffe H, Pant HC. Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer’s NFTs. FASEB J. 2011 Nov;25(11):3896-905. Epub 2011 Aug 9.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

January 5, 2012

Event: Journal Club ” Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer’s disease ”

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 12:38 pm

Laila Abdullah will be presenting the paper on Friday (1/6/2012) at 4:30 PM in Roskamp Institute.

Title: “Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer’s disease ”

Wood PL, Smith T, Lane N, Khan MA, Ehrmantraut G, Goodenowe DB. Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer’s disease. Lipids Health Dis. 2011 Dec 5;10(1):227. [Epub ahead of print]

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

December 6, 2011

Special guest speaker

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 1:46 pm
Dr. Cathy Walsh, PhD
Manager and Senior Scientist, Marine Immunology Program,
Mote Marine Laboratory

will present:

Pathways of Programmed Cell Death in Tumor Cells Exposed
to Shark Immune Cell-Derived Peptides

Friday, December 9, 2011 at 3:30 pm
 in the Roskamp Institute Auditorium 

This is the first in a symposium series where scientists from the Mote Marine Laboratory and the Roskamp Institute will meet to discuss recent scientific work
being conducted at each respective research facility.

November 28, 2011

Event: Journal Club ” Protective effect of e-viniferin on b-amyloid peptide aggregation investigated by electrospray ionization mass spectrometry “

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 12:03 pm

Robert Pelot will be presenting the paper on Friday (12/02/2011) at 4:00 PM in Roskamp Institute.

Title: ” Protective effect of e-viniferin on b-amyloid peptide aggregation investigated by electrospray ionization mass spectrometry ”

Protective effect of e-viniferin on b-amyloid peptide aggregation investigated by electrospray ionization mass spectrometry.Tristan Richard , Pascal Poupard, Merian Nassra, Yorgos Papastamoulis, Marie-Laure Iglésias, Stéphanie Krisa, Pierre Waffo-Teguo, Jean-Michel Mérillon, Jean-Pierre Monti. Bioorganic & Medicinal Chemistry 19 (2011) 3152–3155

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

November 9, 2011

Event: Journal Club ” Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor “

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 2:00 pm


Scott Ferguson will be presenting the paper on Friday (11/11/2011) at 4:00 PM in Roskamp Institute.

Title: ” Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor ”

Ressler, K. J., Mercer, K. B., Bradley, B., Jovanovic, T., Mahan, A., Kerley, K., Norrholm, S. D., Kilaru, V., Smith, A. K., Myers, A. J., Ramirez, M., Engel, A., Hammack, S. E., Toufexis, D., Braas, K. M., Binder, E. B. and May, V., Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature. 470, 492-497.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

State College of Florida’s A.S. Biotechnology program on November 8, 2011.

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 1:57 pm

The Roskamp Institute’s Dr Ghania Ait-Ghezala and James Humphrey are guest speakers for the State College of Florida’s A.S. Biotechnology program on November 8, 2011. Dr Ait-Ghezala and Mr. Humphrey will be talking on Genetic Testing and the Ethics of Genetic Testing.  The Roskamp Institute strongly supports education in the sciences. The Roskamp Institute is a not-for-profit organization and Dr Mike Mullan is CEO of the Roskamp Institute.

November 1, 2011

Event: Journal Club “Single particle analysis of tau oligomer formation induced by metal ions and organic solvents “

Filed under: Uncategorized — Tags: — Gogce Crynen @ 12:25 pm

Benoit Mouzon will be presenting the paper on Friday (11/04/2011) at 4:00 PM in Roskamp Institute.

Title: ” Single particle analysis of tau oligomer formation induced by metal ions and organic solvents ”

Single particle analysis of tau oligomer formation induced by metal ions and organic solvents. Bader B, Nübling G, Mehle A, Nobile S, Kretzschmar H, Giese A. Biochem Biophys Res Commun. 2011 Jul 22;411(1):190-6. Epub 2011 Jun 24.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

October 27, 2011

Event: Journal Club ” Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis “

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 9:32 am

Robert Pelot will be presenting the paper on Friday (10/28/2011) at 4:00 PM in Roskamp Institute.

Title: ” Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis”

Diane P. Hanger, Helen L. Byers, Selina Wray, Kit-Yi Leung, Malcolm J. Saxton, Anjan Seereeram, C. Hugh Reynolds, Malcolm A. Ward, and Brian H. Anderton. Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis, J. Biol. Chem., Vol. 282, Issue 32, 23645-23654, August 10, 2007.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

October 10, 2011

Event: Journal Club Early TBI-Induced Cytokine Alterations are Similarly Detected by Two Distinct Methods of Multiplex Assay “

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 5:20 pm


Scott Ferguson will be presenting the paper on Friday (10/14/2011) at 4:00 PM in Roskamp Institute.

Title: “Early TBI-Induced Cytokine Alterations are Similarly Detected by Two Distinct Methods of Multiplex Assay ”

Mukherjee, S., Katki, K., Arisi, G. M., Foresti, M. L. and Shapiro, L. A., Early TBI-Induced Cytokine Alterations are Similarly Detected by Two Distinct Methods of Multiplex Assay. Front Mol Neurosci. 4, 21.Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

October 3, 2011

Event: Journal Club ” Nitration of Tyrosine 10 Critically Enhances Amyloid β Aggregation and Plaque Formation “

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 12:05 pm

Alex Bishop will be presenting the paper on Friday (10/07/2011) at 4:00 PM in Roskamp Institute.

Title: ” Nitration of Tyrosine 10 Critically Enhances Amyloid β Aggregation and Plaque Formation ”

Markus P. Kummer, Michael Hermes, Andrea Delekarte, Thea Hammerschmidt, Sathish Kumar, Dick Terwel, Jochen Walter, Hans-Christian Pape, Simone König, Sigrun Roeber, Frank Jessen, Thomas Klockgether, Martin Korte, Michael T. Heneka, Nitration of Tyrosine 10 Critically Enhances Amyloid β Aggregation and Plaque Formation, Neuron, Volume 71, Issue 5, 8 September 2011, Pages 833-844, ISSN 0896-6273, 10.1016/j.neuron.2011.07.001.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

September 28, 2011

Event: Journal Club ” The potential role of JAK2/STAT3 pathway on the anti-apoptotic effect of recombinant human erythropoietin (rhEPO) after experimental traumatic brain injury of rats ” and ” Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor”

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 10:10 pm

Benoit Mouzon will be presenting the paper on Friday (9/30/2011) at 4:00 PM in Roskamp Institute.

Title: ” The potential role of JAK2/STAT3 pathway on the anti-apoptotic effect of recombinant human erythropoietin (rhEPO) after experimental traumatic brain injury of rats ” and ” Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor”

The potential role of JAK2/STAT3 pathway on the anti-apoptotic effect of recombinant human erythropoietin (rhEPO) after experimental traumatic brain injury of rats. Zhao J, Li G, Zhang Y, Su X, Hang C. Cytokine. 2011 Aug 13.

Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor. Xiong Y, Mahmood A, Qu C, Kazmi H, Zhang ZG, Noguchi CT, Schallert T, Chopp M. J Neurotrauma. 2010 Jan;27(1):205-15.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

September 8, 2011

Event: Journal Club ” A CaMKIIβ signaling pathway at the centrosome regulates dendrite patterning in the brain “

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 2:30 pm

Chris Kline will be presenting the paper on Friday (9/9/2011) at 4:00 PM in Roskamp Institute.

Title: ” A CaMKIIβ signaling pathway at the centrosome regulates dendrite patterning in the brain.”

Puram SV, Kim AH, Ikeuchi Y, Wilson-Grady JT, Merdes A, Gygi SP, Bonni A. A CaMKIIβ signaling pathway at the centrosome regulates dendrite patterning in the brain. Nat Neurosci. 2011 Jul 3;14(8):973-83.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

August 30, 2011

Event: Journal Club “Stress and traumatic brain injury: a behavioral, proteomics, and histological study “

Filed under: Uncategorized — Tags: , , , , — Gogce Crynen @ 9:51 am

Scott Ferguson will be presenting the paper on Friday (9/2/2011) at 4:00 PM in Roskamp Institute.

Title: ” Stress and traumatic brain injury: a behavioral, proteomics, and histological study.”

Kwon, S. K., Kovesdi, E., Gyorgy, A. B., Wingo, D., Kamnaksh, A., Walker, J., Long, J. B. and Agoston, D. V.,2011. Stress and traumatic brain injury: a behavioral, proteomics, and histological study. Front Neurol. 2, 12.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

August 15, 2011

Event: Journal Club ” Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer’s disease models.”

Filed under: Uncategorized — Tags: , , , , — Gogce Crynen @ 10:44 am

Laila Abdullah will be presenting the paper on Friday (8/19/2011) at 4:00 PM in Roskamp Institute.

Title: ” Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer’s disease models.”

Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer’s disease models. PLoS One. 2011 Jan 5;6(1):e15816.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

August 2, 2011

Event: Journal Club ” The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains.”

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 10:45 am

Benoit Mouzon will be presenting the paper on Friday (8/5/2011) at 4:00 PM in Roskamp Institute.

Title: ” The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains.”

Corrigan F, Pham CL, Vink R, Blumbergs PC, Masters CL, van den Heuvel C, Cappai R. The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains.Brain Res. 2011 Mar 10;1378:137-43. Epub 2011 Jan 6.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

July 26, 2011

Event: Journal Club ” Nicotinic acetylcholine receptor signalling: roles in Alzheimer’s disease and amyloid neuroprotection.” and ” Alpha7 neuronal nicotinic receptors: the missing link to understanding Alzheimer’s etiopathology?”

John Phillips will be presenting the paper on Friday (7/29/2011) at 4:00 PM in Roskamp Institute.

Title: ” Nicotinic acetylcholine receptor signalling: roles in Alzheimer’s disease and amyloid

neuroprotection.” and ” Alpha7 neuronal nicotinic receptors: the missing link to understanding Alzheimer’s etiopathology?”

Buckingham SD, Jones AK, Brown LA, Sattelle DB. Nicotinic acetylcholine

receptor signalling: roles in Alzheimer’s disease and amyloid

neuroprotection. Pharmacol Rev. 2009 Mar;61(1):39-61. Epub 2009 Mar 16.

Bencherif M, Lippiello PM. Alpha7 neuronal nicotinic receptors: the missing

link to understanding Alzheimer’s etiopathology? Med Hypotheses. 2010

Feb;74(2):281-5. Epub 2009 Oct 1.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

July 19, 2011

Event: Journal Club ” Blast exposure in rats with body shielding is characterized primarily by diffuse axonal injury “

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 9:24 am

Scott Ferguson will be presenting the paper on Friday (7/22/2011) at 4:00 PM in Roskamp Institute.


Title: ” Blast exposure in rats with body shielding is characterized primarily by diffuse axonal injury ”

Garman RH, Jenkins LW, Switzer RC, Bauman RA, Tong LC, Swauger PV, Parks SA, Ritzel DV, Dixon CE, Clark RS, Bayır H, Kagan V, Jackson EK, Kochanek PM.Blast exposure in rats with body shielding is characterized primarily by diffuse axonal injury. 2011 J Neurotrauma. Jun;28(6):947-59.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

July 13, 2011

Event: Journal Club ” Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration.”

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 9:57 am

Alex Bishop will be presenting the paper on Friday (7/15/2011) at 4:00 PM in Roskamp Institute.

Title: ” Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration ”

Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, Louie JY, Wu T, Scearce-Levie K, Patrick C, Adame A, Giorgini F, Moussaoui S, Laue G, Rassoulpour A, Flik G, Huang Y, Muchowski JM, Masliah E, Schwarcz R, Muchowski PJ. 2011. Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration. Cell 145, 863–874

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

July 5, 2011

Event: Journal Club “Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid.”

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 11:28 am

Laila Abdullah will be presenting the paper on Friday (7/8/2011) at 4:00 PM in Roskamp Institute.

Title: ” Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid ”

He C, Qu X, Cui L, Wang J, Kang JX. Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11370-5

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

June 20, 2011

Event: Journal Club ” Concussive brain trauma in the mouse results in acute cognitive deficits and sustained impairment of axonal function.”

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 1:24 pm

Benoit Mouzon will be presenting the paper on Friday (6/24/2011) at 4:00 PM in Roskamp Institute.


Title: ” Concussive brain trauma in the mouse results in acute cognitive deficits and sustained impairment of axonal function ”

Creed JA, DiLeonardi AM, Fox DP, Tessler AR, Raghupathi R. Concussive brain trauma in the mouse results in acute cognitive deficits and sustained impairment of axonal function. J Neurotrauma. 2011 Apr;28(4):547-63.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

June 13, 2011

Event: Journal Club” Influence of a Brief Episode of Anesthesia during the Induction of Experimental Brain Trauma on Secondary Brain Damage and Inflammation. “

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 4:10 pm

Scott Ferguson will be presenting the paper on Friday (6/17/2011) at 4:00 PM in Roskamp Institute.

Title: Influence of a Brief Episode of Anesthesia during the Induction of Experimental Brain Trauma on Secondary Brain Damage and Inflammation.

Luh C, Gierth K, Timaru-Kast R, Engelhard K, Werner C, Thal SC. Influence of a Brief Episode of Anesthesia during the Induction of Experimental Brain Trauma on Secondary Brain Damage and Inflammation. PLoS One. 2011;6(5):e19948. Epub 2011 May 19.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

May 31, 2011

Event: Journal Club” Krill phosphatidylserine improves learning and memory in Morris water maze in aged rats “

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 1:32 pm

Laila Abdullah will be presenting the paper on Friday (6/3/2011) at 4:00 PM in Roskamp Institute.


Title: Krill phosphatidylserine improves learning and memory in Morris water maze in aged rats

Lee B, Sur BJ, Han JJ, Shim I, Her S, Lee HJ, Hahm DH. Krill phosphatidylserine improves learning and memory in Morris water maze in aged rats. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):1085-93.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

May 25, 2011

ALZHEIMER’S DISEASE DRUG DEVELOPED AT ROSKAMP INSTITUTE APPROVED FOR KEY CLINICAL TRIAL FUNDING IN EUROPE

Filed under: Uncategorized — Tags: , , , , — Gogce Crynen @ 10:08 am

ALZHEIMER’S DISEASE DRUG DEVELOPED AT ROSKAMP INSTITUTE

APPROVED FOR KEY CLINICAL TRIAL FUNDING IN EUROPE

SARASOTA, FL – An international research consortium led by Trinity College Dublin (Ireland) today announced the selection for funding of a large-scale European clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute in Sarasota. More than 500 Alzheimer’s patients will participate in the multicenter Phase III clinical trial designed to study the effectiveness of Nilvadipine.

“We need many more medicines to move forward into advanced clinical trials in the fight against Alzheimer’s Disease and we are pleased the Roskamp Institute has played such a major role in the development of this drug,” said Michael Mullan, M.D., Ph.D., Roskamp Institute director who, with associate director Fiona Crawford, Ph.D. and lead scientist Daniel Paris, Ph.D., led the research team that developed the drug.  Phase III studies are usually the last step in the regulatory process before a drug can move into clinical practice.

“Only a handful of Alzheimer’s drugs have ever reached this stage, and most were developed by major pharmaceutical companies.  It’s a tremendous achievement for a research institute like ours to be part of the process,” said Crawford.

Brian Lawlor, M.D., Connolly Norman Professor of Old Age Psychiatry at Trinity College Dublin, Ireland, will be principal investigator and coordinator of the US$ 8.4 million Nilvadipine study, which is being funded by the European Commission Seventh Framework Programme.  More than 20 European clinical sites will participate in the placebo-controlled study.  Anticipated to begin in early 2012, patients with mild to moderate Alzheimer’s disease will be recruited to participate.

“Considering the devastating impact that Alzheimer’s disease has on people, there is relatively little research funding being made available to tackle this major killer,” said Lawlor.

The clinical trials will take place in Europe, where Nilvadipine is already approved for use in mild cases of hypertension (high blood pressure). “The process can move more quickly in Europe, and the study findings may help accelerate the process with the U.S. Food and Drug Administration (FDA),” Mullan said.

Mullan and Crawford have been studying Alzheimer’s disease for more than 20 years, moving from the UK to Florida in 1991 and to Sarasota in 2003 to establish the Roskamp Institute.  “Some of our recent studies have involved Sarasota area residents, who have contributed to our understanding of Alzheimer’s disease and helped move the development process forward,” said Crawford.

In the Sarasota laboratories, the research team discovered that Nilvadipine, a drug approved in Europe for treatment of hypertension, can stop the accumulation of the amyloid proteins in the brain – a development that has been implicated in Alzheimer’s disease. A combined Phase I/II clinical trial was completed in Europe by the Institute last year and focused on Nilvadipine’s safety. “The initial results indicated that patients with Alzheimer’s disease were able to tolerate the drug well,”   said Mullan.

Now, the Roskamp Institute will provide research support for the Phase III clinical trial, such as assessing genetic and other markers for Alzheimer’s disease in study participants.

The Institute’s commercial spinoff, Archer Pharmaceuticals, owns the intellectual property rights to Nilvadipine, and Mullan serves as Archer’s chief executive officer.  “There are always risks involved with drug development and discovery,” said Mullan. “But we must continue to invest in new approaches in the worldwide battle against Alzheimer’s disease.”

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. The Institute is located in Sarasota, Florida, and operates a memory clinic onsite.

For more information:  www.rfdn.org

Contact:  Steve Klindt

Tel: 941-752-2949

Email: sklindt@roskampinstitute.org

May 24, 2011

Event: Journal Club ” Inflammation modulates anxiety in an animal model of multiple sclerosis”

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 11:51 am

Helena Chaytow will be presenting the paper on Friday (5/27/2011) at 4:00 PM in Roskamp Institute.

Title: Inflammation modulates anxiety in an animal model of multiple sclerosis

Isabella Peruga, Silvia Hartwig, Jan Thöne, Bernhard Hovemann, Ralf Gold, Georg Juckel and Ralf A. Linker.Behavioural Brain Research, 20 June 2011, Volume 220, Issue 1, Pages 20-29

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

May 16, 2011

May 9, 2011

Event: Journal Club “Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan”

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 10:08 am

Alex Bishop will be presenting the paper on Friday (5/13/2011) at 4:00 PM in Roskamp Institute.

Title: “Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan ”

Nature 472, 226–229 (14 April 2011) doi:10.1038/nature09873

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

May 3, 2011

Event: Journal Club ” Neuronal activity regulates the regional vulnerability to amyloid-β deposition.”

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 11:25 am

John Phillips will be presenting the paper on Friday (5/6/2011) at 4:00 PM in Roskamp Institute.

Title: ” Neuronal activity regulates the regional vulnerability to amyloid-β deposition ”

Nature Neuroscience Published online: 01 May 2011 | doi:10.1038/nn.2801

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

April 18, 2011

Event: Journal Club ” Repeated, intermittent exposures to diisopropylfluorophosphate in rats: protracted effects on cholinergic markers, nerve growth factor-related proteins, and cognitive function.”

Filed under: Uncategorized — Gogce Crynen @ 10:58 am

Laila Abdullah will be presenting the paper on Friday (4/22/2011) at 4:00 PM in Roskamp Institute.

Title: ” Repeated, intermittent exposures to diisopropylfluorophosphate in rats: protracted effects on cholinergic markers, nerve growth factor-related proteins, and cognitive function ”

Neuroscience. 2011 Mar 10;176:237-53. Epub 2010 Dec 24.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

April 15, 2011

VA Research Day, at James A. Haley Veterans’ Hospital, on April 14th 2011

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 9:55 am

Roskamp Institute scientist and Open University PhD students presented posters during VA Research Day, at James A. Haley Veterans’ Hospital, on April 14th 2011. You can find the abstracts of these poster below.

Proteomic-based identification of a CNS biological profile of delayed cognitive impairment in mice exposed to Gulf War agents.

Laila Abdullah,* Alex Bishop,* John Phillips, Scott Ferguson,*†‡ Benoit Mouzon,*†‡*‡ Jon Reed,*† Gogce Crynen,*‡ Myles Mullan,*† Venkat Mathura,* Michael Mullan,*†

Ghania Ait-Ghezala,*†‡ and Fiona Crawford*†‡

*Roskamp Institute, 2040 Whitfield Ave, Sarasota, FL, 34243

†James A. Haley VA Hospital, 13000 Bruce B. Downs Blvd, Tampa, FL, 33612

‡The Open University, Walton Hall, Milton Keynes, MK7 6AA

Background: Gulf War Illness (GWI) is a chronic multisymptom condition with a central nervous system (CNS) component, for which there is no treatment currently available.  It is now believed that the combined exposure to Gulf War (GW) agents, including pyridostigmine bromide (PB) and pesticides, such as permethrin (PER), was a key contributor to the etiology of GWI.  Aim: In this study, a proteomic approach was used to characterize the biomolecular disturbances that accompany neurobehavioral and neuropathological changes associated with combined exposure to PB and PER.  Method: Wild-type CD1 mice were exposed to 2mg/kg PB and 200 mg/kg of PER via i.p. in DMSO daily for 10 days and the control group received DMSO only.  Following exposure, neurobehavioral profile were examined using the Rotarod test to assess motor deficits, the Open Field test for anxiety-related changes and the Morris Water Maze test to assess spatial memory.  Mice were subsequently euthanized for proteomic and histopathological studies.  Results: Mice exposed to PB and PER over 10 days showed an increase in anxiety-like behavior and delayed cognitive impairment compared to control mice that received vehicle only.  Hence, GW agent exposed mice recapitulate the chronic and delayed emergence of the cognitive impairment associated with GWI.  Comparative proteomic approaches showed changes in proteins associated with lipid metabolism and molecular transport in the brains of GW agent exposed mice compared to controls.  Proteins associated with the endocrine and the immune systems were also altered, and dysfunction of these systems is a prominent feature of GWI.  The presence of astrogliosis in the GW agent exposed mice compared to control mice further suggests an immune system imbalance, as is observed in GWI.  Conclusion: These studies provide a broad perspective of the molecular disturbances driving the late pathology of this complex illness.  Evaluation of the potential role of these biological functions in GWI will be useful in identifying molecular pathways to target for development of novel therapeutics for the treatment of GWI.

Funding:

This work is supported by a Congressionally Directed Medical Research Program award to Dr. Fiona Crawford (Grant#: GW080094).

Behavioral outcome in a mouse model of single and multiple concussions

Benoit Mouzon*†, Helena Chaytow*, Corbin Bachmeier*, Michael Mullan*†, and Fiona Crawford*†
*Roskamp Institute, 2040 Whitfield Ave, Sarasota, FL, 34243

†James A. Haley VA Hospital, 13000 Bruce B. Downs Blvd, Tampa, FL, 33612

Abstract:

Concussion or mild traumatic brain injury(mTBI), is the most common type of TBI. The World Health Organization (WHO) estimated that between 70 and 90% of head injuries that receive treatment are mild. Despite its prevalence, mTBI has only recently become accepted as a major health issue since the intense media attention brought to the public on the high incidence of TBI in military conflicts and on high-profile professional athletes. In the United States, every year, more than 2 million people sustain a TBI, principally as a result of falls (35.2%), motor vehicle accidents (17.3%), violence, sports-related injuries and nearby explosions on the battlefield.  An understanding of the cellular mechanisms succeeding TBI is important as this is a major public health problem in industrialized countries.

The purpose of this study is to develop and characterize a novel mTBI model in rodents that replicates the pathological components or phases of human clinical mTBI. This model has several advantages over currently available rodent models of TBI like controlled cortical impact, weight drop, or the fluid percussion model. One advantage of this model is that the location of the hit on the midline allows the whole brain to be used for analyses.  This new model is also of particular interest to investigate military or sports related concussions, where the soldier/athletes usually receive multiple hits over a relatively short period of their lifetime. Repetitive mTBI is believed to be associated with at least two devastating complications.  An increase in brain vulnerability to a second concussive impact and/or 2) chronic cognitive impairments, such as chronic traumatic encephalopathy (CTE), which are often associated with accelerated neurodegeneration in specific brain regions.  These  data validate our model of mild head injury and demonstrate a temporal window of vulnerability to repetitive head trauma that results in behavioral dysfunction.

APP is Internalized After CD40 Ligation Which Increases Aβ Production

Ghania Ait-Ghezala1,2, Ekta Shah1, Jeremy Frieling1, Helena Chaytow1, Claude-Henry Volmar3,and Michael J. Mullan1,2

1Roskamp Institute, Sarasota, FL 34243.  2James A. Haley Veterans’ Hospital, Tampa, FL 33612.  3Scripps Research Institute, Jupiter, FL 33458.

ABSTRACT

CD40, a member of the tumor necrosis factor receptor superfamily, and its cognate ligand CD40L both have elevated levels in the brains of Alzheimer’s disease (AD) patients compared to controls. We have shown that pharmacological or genetic interruption of CD40/CD40L interaction results in mitigation of AD-like pathology in vivo in transgenic AD mouse models, and in vitro. Previously we showed that CD40L stimulation induces Ab production potentially through the g-secretase. Particularly we report an increase in levels of Ab (1-40) and Ab (1-42). We have also recently shown that CD40 ligation triggers internalization of APP, and that internalization by endocytosis is associated with increased Ab production. To further test whether lipid raft translocation of APP is indeed triggered by CD40 ligation, we have expressed a CD40/CD45 chimera in vitro. We will ultimately use this chimera to measure the impact of ligation on Ab production.

CD40 Ligand Deficiency Improves Rate of Functional Recovery Following Traumatic Brain Injury

Scott Ferguson1,2, Benoit Mouzon1,2, John Phillips1, Gogce Kayihan1,2, Helena Chaytow1, Alex Bishop1, Laila Abdullah1, Myles Mullan1, Venkatarajan Mathura1,2, Michael Mullan1,2, Fiona Crawford1,2

1Roskamp Institute, 2040 Whitfield Ave, Sarasota, FL, 34243

2James A. Haley VA Hospital, 13000 Bruce B. Downs Blvd, Tampa, FL, 33612

Abstract

Traumatic brain injury (TBI) has been diagnosed in 178,876 service members from 2000 to the first quarter of 2010. The neurobehavioral sequelae of TBI persist long after the injury, which consists of both a primary insult to the brain as well as secondary injury that occurs in the hours and days immediately thereafter.  In order to find targets for therapeutic intervention we have analyzed the proteomic profile of the response to injury by Apolipoprotein E (APOE) transgenic mice.  Polymorphisms in APOE are known to impact the outcome after TBI, with the APOE4 allele (and concomitant ApoE4 expressed protein) associated with worse outcome than ApoE3 following TBI.

Proteomic analysis of the response to injury by APOE transgenic mice revealed multiple pathways differentially regulated in APOE3 and APOE4 mice following injury, suggesting a potential role of those pathways in modulating the outcome from injury.  One of these pathways involved CD40-related molecules.  CD40 and its ligand, CD154, have been shown to be upregulated in patients following cerebral ischemia (Garlichs et al, 2003). A study by Ishikawa et al (2005) also showed CD40 and CD40 ligand deficient mice have reduced infarct volume in a mouse model of ischemia, and given that ischemic conditions are known to occur in the brain following TBI, we used CD40 ligand (CD40L) knockout mice (Jackson Laboratories) to study the effect of CD40 signaling in a CCI model of severe TBI.

Rotarod testing was used to evaluate neuromotor skills and the Barnes maze was employed to test spatial learning and memory.  Our results showed that CD40L knockout mice showed an improved rate of functional recovery following TBI compared to wild type controls, as well as improved performance on both the Rotarod and Barnes maze tasks overall.

April 11, 2011

News: James Humphrey will talk at Suncoast workforce Bi-County Healthcare Commitee

Filed under: Uncategorized — Gogce Crynen @ 5:14 pm

COO of Roskamp Institute, Mr James Humphrey will talk at Bi-County Healthcare Committee meeting organized by Suncoast workforce. The meeting will be held on Wednesday , April 13, 2011, 8 AM at 3660 N. Washington Blvd. Sarasota FL 34234.

Event: Journal Club ” Psychosis in Alzheimer’s Disease in the National Alzheimer’s Disease Coordinating Center Uniform Data Set: Clinical Correlates and Association with Apolipoprotein E ” and ” Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain-barrier model “

Filed under: Uncategorized — Tags: , , , , , , , — Gogce Crynen @ 2:13 pm

Ekta Shah will be presenting the paper on Friday (4/15/2011) at 4:00 PM in Roskamp Institute.

Title: ” Psychosis in Alzheimer’s Disease in the National Alzheimer’s Disease Coordinating Center Uniform Data Set: Clinical Correlates and Association with Apolipoprotein E ” and ” Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain-barrier model ”

International Journal of Alzheimer’s Disease, Volume 2011 (2011), Article ID 926597, 8 pages

doi:10.4061/2011/926597 and  JBC, 2011, doi: 10.1074/jbc.M111.225532 , respectively.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

April 4, 2011

Event: Journal Club ” Mechanical Tissue Resuscitation Treatment Reduces Brain Tissue Volume and Intracerebral Hemorrhage and Increases Blood Perfusion in a Traumatic Brain Injury Model in Swine” and “Efficacy and mechanisms of vacuum-assisted closure (VAC) therapy in promoting wound healing: a rodent model”

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 5:27 pm

Benoit Mouzon will be presenting the paper on Friday (4/08/2011) at 4:00 PM in Roskamp Institute.

Title: ” Mechanical Tissue Resuscitation Treatment Reduces Brain Tissue Volume and Intracerebral Hemorrhage and Increases Blood Perfusion in a Traumatic Brain Injury Model in Swine” and “Efficacy and mechanisms of vacuum-assisted closure (VAC) therapy in promoting wound healing: a rodent model”

2010, Conference paper, http://handle.dtic.mil/100.2/ADA532538 and J Plast Reconstr Aesthet Surg. 2009 Oct;62(10):1331-8. Epub 2008 Jul 9, respectively.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

March 29, 2011

Event: Journal Club “Molecular regulation of sexual preference revealed by genetic studies of 5-HT in the brains of male mice”

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 10:03 am

Helena Chaytow will be presenting the paper on Friday (4/1/2011) at 4:00 PM in Roskamp Institute.

Title: Molecular regulation of sexual preference revealed by genetic studies of 5-HT in the brains of male mice

Nature(2011) doi:10.1038/nature09822

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

March 23, 2011

Event: Journal Club “Dual vulnerability of tau to calpains and caspase-3 proteolysis under neurotoxic and neurodegenerative conditions”

Filed under: Uncategorized — Tags: , , , , — Gogce Crynen @ 10:35 am

Scott Ferguson will be presenting the paper on Friday (3/25/2011) at 4:00 PM in Roskamp Institute.

Title: Dual vulnerability of tau to calpains and caspase-3 proteolysis under neurotoxic and neurodegenerative conditions

ASN Neuro. 2011 Feb 16;3(1):e00051.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

March 14, 2011

Event: Journal Club “Reversing EphB2 depletion rescues cognitive functions in Alzheimer model”

Filed under: Uncategorized — Tags: , , , , — Gogce Crynen @ 2:24 pm

John Phillips will be presenting the paper on Friday (3/18/2011) at 4:00 PM in Roskamp Institute.

Title: Reversing EphB2 depletion rescues cognitive functions in Alzheimer model

6 JANUARY 201 1 | VOL 469 | NATURE | 47

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

March 7, 2011

Event: Journal Club “High ability of apolipoprotein E4 to stabilize amyloid-peptide oligomers, the pathological entities responsible for Alzheimer’s disease”

Filed under: Uncategorized — Tags: , , , , , — Gogce Crynen @ 11:27 am

Laila Abdullah will be presenting the paper on Friday (3/4/2011) at 4:00 PM in Roskamp Institute.


Title: High ability of apolipoprotein E4 to stabilize amyloid-peptide oligomers, the pathological entities responsible for Alzheimer’s disease

FASEB J. 2011 Jan 25. [Epub ahead of print]

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

March 3, 2011

Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine

Filed under: Uncategorized — Tags: , , , , — Gogce Crynen @ 10:13 am

February 14, 2011

Dr. Corbin Bachmeier of the Roskamp Institute and Dr. Gary Levin of the University of Southern Nevada recently published an article in Biopharmaceutics and Drug Disposition titled “Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine”.  They observed that venlafaxine induced drug efflux protein expression in cell culture, whereas its metabolite, desvenlafaxine, had no impact on drug efflux protein levels.  They are currently exploring this phenomenon further in an in vivo paradigm through a grant provided by Pfizer.

Abstract

Venlafaxine and its metabolite desvenlafaxine are serotonin-norepinephrine reuptake inhibitors currently prescribed for the treatment of depression.  Previously, we reported venlafaxine is an inducer of MDR1, the gene responsible for P-glycoprotein (P-gp).  In the present study, we expanded upon these findings by examining the effect of venlafaxine and desvenlafaxine on the expression of both P-gp and the breast cancer resistance protein (BCRP) in human brain endothelial cells (HBMEC), an in vitro model of the blood-brain barrier (BBB).  The HBMEC were treated for 1 hour with various concentrations (500nM to 50µM) of venlafaxine and desvenlafaxine.  Western blot analysis revealed treatment with venlafaxine significantly induced the expression of P-gp (2-fold) and BCRP (1.75-fold) in a dose-dependent manner, while treatment with desvenlafaxine had no effect on drug efflux transporter expression.  To determine the functional significance of this effect, we examined the permeability of a known drug efflux probe, rhodamine 123, across the BBB model and Caco-2 cells, a model of intestinal absorption.  Treatment with venlafaxine (1µM to 50µM) for 1 hour significantly reduced the apical-to-basolateral permeability of R123 across the BBB model (30%) and Caco-2 cell monolayers (25%), indicative of increased drug efflux transporter expression at the apical membrane.  Conversely, desvenlafaxine had no effect on R123 permeability in either cellular model.  These studies indicate that venlafaxine, but not desvenlafaxine is an inducer of drug efflux transporter expression, which consequently increases the potential for clinical drug-drug interactions.  Therefore, based on these preliminary results, caution should be taken when prescribing venlafaxine with other P-gp substrates.

February 28, 2011

Event: Journal Club “Identification of Candidate IgG Biomarkers for Alzheimer’s Disease via Combinatorial Library Screening”

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 3:07 pm

Alex Bishop will be presenting the paper on Friday (3/4/2011) at 4:00 PM in Roskamp Institute.

Title: Identification of Candidate IgG Biomarkers for Alzheimer’s Disease via Combinatorial Library Screening

Cell 144, 132–142, January 7, 2011

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

February 25, 2011

Epitope-dependent effects of beta-amyloid antibodies on beta-amyloid clearance in an in vitro model of the blood-brain barrier

Filed under: Uncategorized — Tags: , , , , — Gogce Crynen @ 11:03 am

February 14, 2011

Dr. Bachmeier and Dr. Paris recently published an article in Microcirculation titled “Epitope-dependent effects of beta-amyloid antibodies on beta-amyloid clearance in an in vitro model of the blood-brain barrier”.  This report offers an explanation as to why some antibody-based immunotherapies are more effective than others in lowering brain amyloid levels in AD.

Abstract

Objective: To investigate the role of the receptor for advanced glycation end products (RAGE) in the epitope-dependent effects of beta-amyloid (Aβ) antibodies used as a peripheral sink therapy in Alzheimer’s disease.

Methods: An in vitro model of the blood-brain barrier (BBB) was used to examine the effect of various Aβ antibodies or Aβ peptide fragments on Aβ exchange across the BBB.

Results: An N-terminal Aβ antibody significantly enhanced the basolateral-to-apical transcytosis of fluorescein-Aβ(1-42) across the BBB model (41%), while no effect was apparent with a C-terminal Aβ antibody.  Interestingly, modulation of RAGE in the presence of a C-terminal Aβ antibody resulted in a 65% increase in Aβ clearance of across the BBB model, suggesting the C-terminal antibody-Aβ complex is susceptible to RAGE transport.  Additionally, N-terminal peptide fragments of Aβ attenuated the brain penetration of full length Aβ in the BBB model, indicating the N-terminal region of Aβ is required for brain uptake.

Conclusions: Antibodies masking the N-terminal region of Aβ increase Aβ clearance across the BBB by preventing Aβ from interacting with the RAGE transporter, whereas antibodies bound to the C-terminus of Aβ are taken up by RAGE and, hence, do not influence the BBB clearance of Aβ.

February 21, 2011

Event: Journal Club “Tau-Induced Defects in Synaptic Plasticity, Learning, and Memory Are Reversible in Transgenic Mice after Switching Off the Toxic Tau Mutant”

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 11:15 am

Benoit Mouzon will be presenting the paper on Friday (2/25/2011) at 4:00 PM in Roskamp Institute.

Title: Tau-Induced Defects in Synaptic Plasticity, Learning, and Memory Are Reversible in Transgenic Mice after Switching

Off the Toxic Tau Mutant.

The Journal of Neuroscience, February 16, 2011 • 31(7):2511–2525 • 2511

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

February 17, 2011

A grant from Pfizer to study the effect of two antidepressant medications for Roskamp Institute Scientist

1-13-2011

Dr. Corbin Bachmeier of the Roskamp Institute in collaboration with Dr. Gary Levin of the University of Southern Nevada recently received a grant from Pfizer to study the effect of two antidepressant medications currently on the market, venlafaxine (Effexor) and desvenlafaxine (Pristiq), on the expression of the drug efflux transport proteins P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in vivo.  This work is a continuation of their previous efforts, supported through a grant from Wyeth Pharmaceuticals, which determined that venlafaxine induces drug efflux protein expression in brain endothelial cells, an in vitro model of the blood-brain barrier (BBB), in a dose dependant manner.  Moreover, these effects were functionally significant as treatment with venlafaxine reduced the permeability of a known drug efflux probe, rhodamine 123, across the BBB model and Caco-2 cell monolayers, a model of intestinal absorption.  Conversely, treatment with desvenlafaxine in the BBB model did not result in a statistically significant change in the expression of either P-gp or BCRP nor did desvenlafaxine impact the permeability of R123 across the BBB model or Caco-2 monolayers.  As it is difficult to predict clinical outcomes based solely on in vitro observations, the current in vivo studies will examine the impact of these compounds on drug efflux protein expression in a live animal.  In doing so, these studies will provide a better understanding of the potential for drug-drug interactions and the relevance of these effects to a clinical setting.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

February 7, 2011

Event: Journal Club “Neurogenesis in Adult Human Brain after Traumatic Brain Injury. ”

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 3:39 pm

Scott Ferguson will be presenting the paper on Friday (2/11/2011) at 4:00 PM in Roskamp Institute.

Title: Neurogenesis in Adult Human Brain after Traumatic Brain Injury.

J Neurotrauma. 2011 Jan 30. [Epub ahead of print]

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

February 1, 2011

Event: Journal Club “Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer’s disease. ”

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 10:09 am

Ekta Shah will be presenting the paper on Friday (2/4/2011) at 4:00 PM in Roskamp Institute.

Title: Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer’s disease.

J Biol Chem. 2010 Nov 30. [Epub ahead of print]

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

January 24, 2011

Event: Journal Club “Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis “

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 1:21 pm

Laila Abdullah will be presenting the paper on Friday (1/28/2011) at 4:00 PM in Roskamp Institute.

Title: Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis

PNAS July 6, 2010 vol. 107 no. 27 12233-12238

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

January 17, 2011

Event: Journal Club “The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer’s disease and related tauopathies”

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 10:15 am

Chris Mayer will be presenting the paper on Friday (1/21/2011) at 4:00 PM in Roskamp Institute.

Title: The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer’s disease and related tauopathies

Pharmacol Res. 2010 Dec 14. [Epub ahead of print]

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

January 4, 2011

Event: Journal Club “Synergistic benefits of erythropoietin and simvastatin after traumatic brain injury”

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 1:56 pm


Helena Chaytow will be presenting the paper on Friday (1/7/2011) at 4:00 PM in Roskamp Institute.

Title: Synergistic benefits of erythropoietin and simvastatin after traumatic brain injury

Brain Res. 2010 Nov 11;1360:177-92. Epub 2010 Sep 15.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

December 22, 2010

Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier

Abstract

Several large population based or clinical trial studies have suggested that certain dihydropyridine (DHP) L-type calcium channel blockers (CCBs) used for the treatment of hypertension may confer protection against the development of Alzheimer’s disease (AD). However, other studies with drugs of the same class have shown no beneficial clinical effects. In order to determine whether certain DHPs are able to impact underlying disease processes in AD (specifically the accumulation of the Alzheimer’s Aβ peptide), we investigated the effect of several antihypertensive DHPs and non-DHP CCBs on Aβ production. Among the antihypertensive DHPs tested, a few, including nilvadipine, nitrendipine and amlodipine inhibited Aβ production in vitro whereas others had no effect or raised Aβ levels. In vivo, nilvadipine and nitrendipine acutely reduced brain Aβ levels in a transgenic mouse model of AD (Tg PS1/APPsw) and improved Aβ clearance across the blood-brain barrier (BBB) whereas amlodipine and nifedipine were ineffective showing that the Aβ lowering activity of the DHPs is independent of their antihypertensive activity. Chronic oral treatment with nilvadipine decreased Aβ burden in the brains of Tg APPsw (Tg2576) and Tg PS1/APPsw mice and also improved learning abilities and spatial memory. Our data suggest that the clinical benefit conferred by certain antihypertensive DHPs against AD is unrelated to their antihypertensive activity but rely on their ability to lower brain Aβ accumulation by affecting both Aβ production and Aβ clearance across the BBB.

Paris DBachmeier CPatel NQuadros AVolmar CHLaporte VGaney JBeaulieu-Abdelahad DAit-Ghezala GCrawford FMullan MJ.

Mol Med. 2010 Dec 17. [Epub ahead of print]

Characterization and Use of Human Brain Microvascular Endothelial Cells to Examine β-amyloid Exchange in the Blood-Brain Barrier

Dr. Bachmeier and Dr. Paris recently published an article in Cytotechnology entitled “Characterization and Use of Human Brain Microvascular Endothelial Cells to Examine β-amyloid Exchange in the Blood-Brain Barrier”. They are currently using this model of the BBB to elucidate the mechanisms responsible for the removal of β-amyloid from the brain. In addition, this model is being used as a screen to identify molecules that facilitate β-amyloid clearance across the BBB with the goal of discovering a new class of therapies for the treatment of Alzheimer’s disease.

Abstract Alzheimer’s disease (AD) is characterized by excessive cerebrovascular deposition of the β-amyloid peptide (Aβ). The investigation of Aβ transport across the blood-brain barrier (BBB) has been hindered by inherent limitations in the cellular systems currently used to model the BBB, such as insufficient barrier properties and poor reproducibility. In addition, many of the existing models are not of human or brain origin and are often arduous to establish and maintain. Thus, we characterized an in vitro model of the BBB employing human brain microvascular endothelial cells (HBMEC) and evaluated its utility to investigate Aβ exchange at the blood-brain interface. Our HBMEC model offers an ease of culture compared with primary isolated or coculture BBB models and is more representative of the human brain endothelium than many of the cell lines currently used to study the BBB. In our studies, the HBMEC model exhibited barrier properties comparable to existing BBB models as evidenced by the restricted permeability of a known paracellular marker. In addition, using a simple and rapid fluormetric assay, we showed that antagonism of key Aβ transport proteins significantly altered the bi-directional transcytosis of fluorescein-Aβ (1-42) across the HBMEC model. Moreover, the magnitude of these effects was consistent with reports in the literature using the same ligands in existing in vitro models of the BBB. These studies establish the HBMEC as a representative in vitro model of the BBB and offer a rapid fluorometric method of assessing Aβ exchange between the periphery and the brain.

December 7, 2010

Event: Journal Club “A Bacterium That Can Grow by Using Arsenic Instead of Phosphorus”

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 4:04 pm


Scott Ferguson will be presenting the paper on Friday (12/10/2010) at 4:00 PM in Roskamp Institute.

Title: A Bacterium That Can Grow by Using Arsenic Instead of Phosphorus

www.sciencexpress.org / 2 December 2010 / Page 1 / 10.1126/science.1197258

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

November 16, 2010

Event: Journal Club, Neuroscience San Diego 2010 meeting highlights

Filed under: Uncategorized — Tags: , , , , — Gogce Crynen @ 10:51 am
Please join us at 4:00 pm this Friday at the Roskamp Institute for Journal Club. We will have a special presentation by Laila Abdullah, Scott Ferguson, and Benoit Mouzon of the highlights of the 2010 Society for Neuroscience conference.

Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

November 11, 2010

Event: Journal Club “Biochemical and neurochemical sequelae following mild traumatic brain injury: summary of experimental data and clinical implications”

Filed under: Uncategorized — Tags: — Gogce Crynen @ 11:32 am

Benoit Mouzon will be presenting the paper on Friday (11/12/2010) at 4:00 PM in Roskamp Institute.

Title: Biochemical and neurochemical sequelae following mild traumatic brain injury: summary of experimental data and clinical implications

Neurosurg Focus 29 (5):E1, 2010

Journal Club is held every Friday. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

November 3, 2010

Wednesday, November 10, 2010

Filed under: Uncategorized — Gogce Crynen @ 5:32 pm

The Tri-Chamber Business After Hours Expo will be held at the Sarasota-Manatee Convention Center where over 1400 members/guests from Sarasota, Manatee, and Venice Area Chambers will converge to network and view each other’s products and services.  The Roskamp Institute will show representation at their Sponsored Booth.

The Roskamp Institute Memory Clinic and Clinical Trials Division provide a full range of services for individuals with Alzheimer’s disease including diagnostic work-up and follow-up treatment, neuropsychological examination, clinical trial opportunities, and memory screening.  For more information, please call (941) 256-8018.

Event: Journal Club “Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease”

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 5:24 pm

John Phillips will be presenting the paper on Friday (11/05/2010) at 4:30 PM in Roskamp Institute.

Title: Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease.

Vol 467| 2 September 2010| doi:10.1038/nature09325

Journal Club is held every Friday. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

October 4, 2010

Event: Journal Club “ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling”

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 1:48 pm

Laila Abdullah will be presenting the paper on Friday (10/08/2010) at 4:30 PM in Roskamp Institute.

Title: ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling.

PNAS | June 29, 2010 | vol. 107 | no. 26 | 12011–12016

Journal Club is held every Friday. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

September 28, 2010

Event: Journal Club “Morphologic and Biochemical Characterization of Brain Injury in a Model of Controlled Blast Overpressure Exposure”

Filed under: Uncategorized — Gogce Crynen @ 12:55 pm

Benoit Mouzon will be presenting the paper on Friday (10/01/2010) at Roskamp Institute.

Title: Morphologic and Biochemical Characterization of Brain Injury in a

Model of Controlled Blast Overpressure Exposure.

The Journal of TRAUMA,2010 Mar 2. [Epub ahead of print]

Journal Club is held every Friday between 4 pm-5pm. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

September 22, 2010

Event: Journal Club “Amyloid-beta-42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism”

Filed under: Uncategorized — Tags: , , , , — Gogce Crynen @ 9:37 am
Laila Abdullah will be presenting the paper on Friday (9/24/2010) at Roskamp Institute.

Title:  Amyloid-beta-42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism.

PNAS, December 8, 2009, vol. 106, no. 49, 20936–20941

Journal Club is held every Friday between 4 pm-5pm. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

September 13, 2010

Title: Effect of VEGF and its receptor antagonist SU-5416, an inhibitor of angiogenesis,on processing of the beta-amyloid precursor protein in primary neuronal cells derived from brain tissue of Tg2576 mice.

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 10:32 am

Nowell (Jim) Ganey will be presenting the paper on Friday (9/17/2010) at Roskamp Institute.

Title:  Effect of VEGF and its receptor antagonist SU-5416, an inhibitor of angiogenesis,on processing of the beta-amyloid precursor protein in primary neuronal cells derived from brain tissue of Tg2576 mice.

Int J Dev Neurosci. 2010 Jul 22. [Epub ahead of print] doi:10.1016/j.ijdevneu.2010.07.231

Journal Club is held every Friday between 4 pm-5pm. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

News:Scientific team at the Roskamp Institute found evidence to support that processes controlling the growth of cerebral blood vessels are altered in the brains of transgenic mouse models of Alzheimer’s disease

Sarasota, Florida). Scientists at the Roskamp Institute in Sarasota, in collaboration with researchers from the H. Lee Moffitt Cancer Center in Tampa, have found laboratory evidence that the processes controlling the growth of cerebral blood vessels are altered  in the brains of transgenic mouse models of Alzheimer’s disease (AD). Scientists say the discovery will provide a better understanding of the role of cerebrovascular lesions in AD brains and may explain why vascular insults synergistically precipitate the cognitive presentation of AD. In addition, their research may provide new therapeutical approaches which are desperately needed to tackle this devastating disorder. AD is the most common form of dementia among the aging population and is characterized by the intracerebral accumulation of a small protein called b-amyloid, as well as, neurofibrillary tangles that form in the neurons of the affected patients. In addition to neuronal damages, AD brains also present evidence of capillary degeneration and a reduction in brain capillary density which probably contribute to the decreased cerebral blood flow reported in all patients suffering from the disease. The growth of blood vessels (or angiogenesis) is controlled by the balance between several growth factors that can stimulate their growth and other molecules that inhibit their formation. The amount of growth factors that normally stimulate angiogenesis is elevated in AD brains, which could suggest that the growth of cerebrovessels would be stimulated in AD. The growth of tumors is dictated by their vascularization, this is particularly true for brain tumors which are highly vascularized. Therefore, in order to determine whether angiogenesis was possibly altered in AD brains, the researchers implanted brain tumors in transgenic mouse models of AD (that have been genetically engineered to reproduce some of the AD brain pathology) as well as normal mice and measured the growth of the tumors in the animals. “Interestingly, we observed that the growth and vascularization of brain tumors was reduced in transgenic mouse models of AD compared to normal mice, suggesting that the AD brain does not constitute a favorable environment to support the growth of new blood vessels.” said Dr. Daniel Paris of the Roskamp Institute, lead author of the study published in the Journal of Neuroscience (J. Neurosci. 2010;30(34):11251-8). “Our data suggest the growth of new brain capillaries that takes place following a stroke for example, and allows for a restoration of the cerebral blood flow in the damage area, will be inhibited in AD. This may explain why vascular insults such as stroke are known to accelerate the cognitive decline in AD patients. Overall, our work suggests that therapies stimulating brain vascularization may be beneficial in AD patients.”, Dr. Paris added. Epidemiological studies have highlighted that the incidence of cancer is reduced in AD patients whereas the prevalence of AD is reduced in patients with an history of cancer suggesting a biological link between cancer and AD. “As the growth of blood vessels is required for the development of tumors, our work suggesting some impairment in the growth of blood vessels in AD may provide a biological mechanism explaining this intriguing relationship between cancer and AD.”, Dr. Paris said. The Roskamp Institute is a not-for-profit research Institute located in Sarasota, Fla., that is dedicated to understanding the causes of, and finding cures for, neuropsychiatric and neurodegenerative disorders with an emphasis on Alzheimer’s disease. The Institute’s Memory Clinic also offers comprehensive cognitive and medical assessment toward differential diagnosis of Alzheimer’s disease and offers treatments and disease management options once the diagnostic evaluation is complete. For more information, please contact the Institute at (941) 752-2949, Roskamp’s Clinical Trials Division in Sarasota at (941) 256-8018 or visit www.RoskampInstitute.com.

News: Roskamp Institute on myFOX Tampa bay

Filed under: Uncategorized — Gogce Crynen @ 9:45 am

myFOX Tampa Bay broad-casted a section on Roskamp Institute, to watch it online please follow the link.

September 8, 2010

Event: Journal Club “Gp91phox (NOX2) in classically activated microglia exacerbates traumatic brain injury”

Filed under: Uncategorized — Tags: , — Gogce Crynen @ 9:50 am

Scott Ferguson will be presenting the paper on Friday (9/10/2010) at Roskamp Institute.


Title:  Gp91phox (NOX2) in classically activated microglia exacerbates traumatic brain injury.

Journal of Neuroinflammation 2010, 7:41      doi:10.1186/1742-2094-7-41

Journal Club is held every Friday between 4 pm-5pm. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

August 18, 2010

Event: Journal Club “AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation”

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 10:59 am

Nowell (Jim) Ganey will be presenting the paper on Friday (8/20/2010) at Roskamp Institute.

Title: AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation

Journal: Neurobiology of Aging.

2010 Jul 16. [Epub ahead of print]  doi:10.1016/j.neurobiolaging.2010.05.026

Journal Club is held every Friday between 4 pm-5pm. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

August 9, 2010

Event: Journal Club “ CD40/CD40 Ligand Signaling in Mouse Cerebral Microvasculature After Focal Ischemia/Reperfusion”

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 10:37 am

Scott Ferguson will be presenting the paper on Friday (8/13/2010) at Roskamp Institute.

Title:  CD40/CD40 Ligand Signaling in Mouse Cerebral Microvasculature After Focal Ischemia/Reperfusion

Journal: Circulation.

2005;111:1690-1696.

Journal Club is held every Friday between 4 pm-5pm. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

July 13, 2010

Greater risk of dementia when spouse has dementia? The Cache County Study

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 9:51 am

New Study Links Marriage and Risk for Dementia A study published in the Journal of the American Geriatric Society reports that spousal caregivers of a dementia patient may have an increased risk for developing dementia themselves. This interesting population based study is the first to empirically explore the effects of caring for a spouse with dementia on caregivers own cognitive status. Results suggest that spouses, particularly male, have a six times greater risk for developing dementia. Prolonged and intense stress may be a major factor in these findings. Norton M, Smith K, Ostbe T et al. Greater risk of dementia when spouse has dementia? The Cache County Study. JAGS 2010; 58:895-900

The Roskamp Institute Memory Clinic and Clinical Trials Division provide a full range of services for individuals with Alzheimer’s disease including diagnostic work-up and follow-up treatment, neuropsychological examination, clinical trial opportunities, and memory screening.  For more information, please call (941) 256-8018.

July 12, 2010

Event: Journal Club “Identification of Caspase-6-Mediated Processing of the Valosin Containing Protein (p97) in Alzheimer’s Disease: A Novel Link to Dysfunction in Ubiquitin Proteasome System-Mediated Protein Degradation”

Chris Mayer will be presenting the paper on Friday (7/16/2010) at Roskamp Institute.

Title: Identification of Caspase-6-Mediated Processing of the Valosin Containing Protein (p97) in Alzheimer’s Disease: A Novel Link to Dysfunction in Ubiquitin Proteasome System-Mediated Protein Degradation

Journal: The Journal of Neuroscience,

April 28, 2010, 30(17):6132-6142

Journal Club is held every Friday between 4 pm-5pm. For change in schedule please check our twitter account or facebook page. Please join us!

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

July 6, 2010

Event: Journal Club Age-dependent effect of apolipoprotein E4 on functional outcome after controlled cortical impact in mice

Filed under: Uncategorized — Gogce Crynen @ 3:27 pm

Benoit Mouzon will be presenting the paper on Friday (7/9/2010) in Roskamp Institute at 4:30pm.

Title: Age-dependent effect of apolipoprotein E4 on functional outcome after controlled cortical impact in mice

Journal: Journal of Cerebral Blood Flow & Metabolism (2010), 1–11

For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

June 28, 2010

Event: Journal Club “Disrupted-in-Schizophrenia-1 expression is regulated by β-site amyloid precursor protein cleaving enzyme-1–neuregulin cascade”

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 10:11 am

Laila Abdullah will be presenting the paper on Friday (7/2/2010) at Roskamp Institute.

Title:Disrupted-in-Schizophrenia-1 expression is regulated by β-site amyloid precursor protein cleaving enzyme-1–neuregulin cascade

Journal: PNAS

5622–5627 | March 23, 2010 | vol. 107 | no. 12

Journal Club is held every Friday between 4 Pm-5pm. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

June 21, 2010

Event: Journal Club “The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer’s disease”

Nowell (Jim) Ganey will be presenting the paper on Friday (6/25/2010) at Roskamp Institute.

Title:The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer’s disease.

Journal : Biomaterials.

2010 Jul;31(21):5608-18. Epub 2010 Apr 28.

Journal Club is held every Friday between 4 Pm-5pm. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949


June 14, 2010

Event: Journal Club “NF-jB activity affects learning in aversive tasks: Possible actions via modulation of the stress axis”

Scott Ferguson will be presenting the paper on Friday (6/18/2010) at Roskamp Institute.

Title:NF-κB activity affects learning in aversive tasks: Possible actions via modulation of the stress axis

Journal: Brain, Behavior, and Immunity

doi:10.1016/j.bbi.2010.04.005

Journal Club is held every Friday between 4 Pm-5pm. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

June 9, 2010

APOLIPOPROTEIN E GENOTYPE AND OXIDATIVE STRESS RESPONSE TO TRAUMATIC BRAIN INJURY

Filed under: Uncategorized — Gogce Crynen @ 10:08 am

By S. FERGUSON,a* B. MOUZON,a G. KAYIHAN, a M. WOOD, a F. POON, a S. DOORE, a V. MATHURA, a

J. HUMPHREY, a B. O’STEEN, b R. HAYES, c A. ROSES, d M. MULLANa AND F. CRAWFORDa

aThe Roskamp Institute, 2040 Whitfield Avenue, 34243, Sarasota, FL,

USA

bCenter for Traumatic Brain Injury Studies, McKnight Brain Institute of

the University of Florida, 100 Newell Drive, Gainesville, FL, USA

cBanyan Biomarkers, 12085 Research Drive, 32615, Alachua, FL,

USA dR. David Thomas Executive Training Center, Duke University, One

Science Drive, Suite 342, Durham, NC, USA

Abstract—Traumatic Brain Injury (TBI) is known to result in oxidative stress, which is an increase or imbalance in the amount of cytotoxic oxidants and free radicals beyond what the cell can normally handle.  The Apolipoprotein E (APOE) gene has different variations called alleles, with two of the most common known as APOE3 and APOE4.  The different APOE alleles have been shown to influence outcome following TBI in different ways, with the APOE4 allele being associated with poor outcome, but through as yet unclear mechanisms, so we used transgenic APOE mouse models to examine the relationship between APOE genotype and oxidative stress following TBI.  Mice transgenic for either human APOE3 or APOE4 on a murine APOE-deficient background were examined in an approved model of TBI. RNA was prepared from the ipsilateral hippocampi and cortices retrieved at 24 h and 1 month post-TBI. Microarray (“gene chip”) analysis was performed on individual samples from three mice per group to determine the way different genes are turned on or off in response to TBI and to specifically investigate the response of genes involved in oxidative stress mechanisms. Our data demonstrated TBI-induced expression of many more anti-oxidant related genes in the APOE3 mice, suggesting a potential anti-oxidative role for the ApoE3 compared to ApoE4. However, in an additional cohort of mice we isolated the ipsilateral hippocampi, cortices, and cerebella at 1 month after TBI for immunohistochemical analysis of markers of oxidative stress: the formation and presence of carbonyls (indication of general oxidative modification), 3-nitrotyrosine (3NT; specific to protein modification), or 4-hydroxyl-2-nonenal (HNE; specific to lipid peroxidation). Although we observed significant increases in all three markers of oxidative stress in response to injury, and genotype was a significant factor for carbonyl and 3NT, we found no significant interaction between genotype and injury. This may be due to the overwhelming effect  injury has on the oxidative stress level compared to genotype in our ANOVA, but nonetheless suggests that an influence on oxidative stress response is not the primary mechanism behind the APOE-genotype specific differences of outcome following TBI.

To reach the article that was published in Neuroscience Volume 168, Issue 3, 14 July 2010, Pages 811-819, please follow the link.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

June 8, 2010

Event Journal Club:Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice

Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice by Rhein et al.

Alex Bishop will be presenting the paper on Friday (6/11/2010) at Roskamp Institute.

Journal Club is held every Friday between 4 Pm-5pm. For change in schedule please check our twitter account or facebook page.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

May 25, 2010

Event: Journal Club

Filed under: Uncategorized — Tags: , , , , — Gogce Crynen @ 10:03 am

Benoit Mouzon will be presenting “Blood-brain barrier breakdown and repair by Src after thrombin-induced injury” by Liu et al.

The journal club will start at 4:00pm on Friday (may 28th 2010) in the auditorium at Roskamp Institute.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

May 18, 2010

Tech Tips, #2: Making a homemade frit for fused silica columns

Filed under: Uncategorized — Tags: , , , , — Gogce Crynen @ 10:24 am

By our own MS guru Jon Reed

A Thermo Engineer once told me that “Nano-LC is not for the faint-of-heart.” A 0.5µl bubble in a 10-port valve can make a mess of an experiment.  Incomplete proteolytic digestions can clog up your brand new $600 column and render it useless.  A few centimeters of post-column dead volume can cause significant peak broadening despite the fact that you have a $50,000 LC system.  The list of problems goes on and on.   This causes more than its share of heartache, which leads to this simple truth:

If the favorite pastime of proteomics researchers is bragging to one another about their latest and snazziest technological acquisitions, then the second favorite pastime is whining about how they don’t work.

Still, as time progresses, people chip away at old problems and find out how to do things better, faster, cheaper.  So this week, I’ll leave you with one less thing to cry about and describe HOW TO MAKE A BETTER HOMEMADE FRIT FOR FUSED SILICA COLUMNS.

I had originally learned to make frits by dipping a piece of fused silica into 75% KASIL and 25% DMF, however these frits were lengthy, un-reproducible, and lead to high back pressure and inconsistent chromatography.  That technique sucks.  Sorry, stinks.  No… wait… it sucks.

A new and improved protocol was first shared with me by Jennifer Busby and Valerie Cavett from Scripps.  They’re very smart, and you should read some of their papers. Go on… log on to Pubmed and get to reading.

It’s an adaption of earlier work by Maiolica et al (Proteomics 2005, 5, 3847–3850), and takes a whopping 2 minutes, and $0.25 of reagents from start to finish.  Well, that doesn’t include the ½ hour drying time, but if you’re saving that kind of time and money for a superior product, don’t complain!

OK, here goes…

  1. Make a Kasil/formamide mix (75/25) and use approximately 2 µL to wet a glass microfiber filter (GC/F, Whatman).
  2. Gently push and twist the end of a fused silica capillary onto the wetted filter.
  3. Dry the frit for 5 minutes at approximately 37ºC or at room temperature for approximately 20 minutes before packing.  Note: times given for a 75 µm capillary; larger diameters may need longer to dry before packing.

Note: different column IDs may require a 2nd glass fiber plug (do not wet this one) to ensure you don’t blow the frit loose.  To do this, first push the end of the fused silica tubing into a dry piece of filter and core out what you need, then repeat this on the wetted section of filter.  You may want to try this using 2 wetted cores, but that may lead to increased back pressure.  The only way to know is to try it out.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

May 6, 2010

Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide

By Daniel Paris • Nikunj Patel • Nowell J. Ganey • Vincent Laporte • Amita Quadros • Michael J. Mullan

Int J Pept Res Ther (2010) 16:23–3.  DOI 10.1007/s10989-010-9198-8

Abstract: The inhibition of angiogenesis is regarded as a promising avenue for cancer treatment. Although some antiangiogenic compounds are in the process of development and testing, these often prove ineffective in vivo, therefore the search for new inhibitors is critical. We have recently identified a ten amino acid fragment of the Alzheimer Ab peptide that is anti-angiogenic both in vitro and in vivo. In the present study, we investigated the antitumoral potential of this decapeptide using human MCF-7 breast carcinoma xenografts in nude mice. We observed that this decapeptide was able to suppress MCF-7 tumor growth more potently than the antiestrogen tamoxifen. Inhibition of tumor vascularization as determined by PECAM-1 immunostaining and decreased tumor cell  proliferation as determined by Ki67 immunostaining were observed following treatment with the Ab fragment. In vitro, this peptide had no direct impact on MCF-7 tumor cell proliferation and survival suggesting that the inhibition of tumor growth and tumor cell proliferation observed in vivo is related to the antiangiogenic activity of the peptide. Taken together these data suggest that this short Ab derivative peptide may constitute a new antitumoral agent.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

April 30, 2010

Roskamp Institute Poster Abstract from VA Reasearch Week

Filed under: Uncategorized — Tags: , , , , , , , , — Gogce Crynen @ 10:22 am

As I mentioned before, most of the PhD students and research assistants from our Institute participated in poster session  that was organized as a part of VA Research Week event series. Here you will find the abstract of our posters, enjoy :)

Development of the Barnes Maze as an Alternative to the Morris Water Maze Following TBI in Mice.

Scott Ferguson1,2, Benoit Mouzon1,2, John Phillips1, Vani Ganapapthi1, Alex Bishop1, Gogce Kayihan1,2, Venkatarajan Mathura1,2, Michael Mullan1,2 , Fiona Crawford1,2

1The Roskamp Institute, Sarasota, FL, USA; 2 James A Haley Veterans Administration, Tampa, FL, USA

Traumatic brain injury (TBI) is suffered by approximately 1.4 million people in the United States each year. TBI is the leading cause of death and disability in the most active population (under 45 years of age) in industrialized countries. Within the military, TBI is associated with 59% of blast-associated injuries seen at Walter Reed Army Medical Center, and between January 2003 and May 2005, 31% of all admissions to WRAMC had a brain injury. Apolipoprotein E (APOE) polymorphisms are known to impact the outcome after TBI, with the APOE4 allele (and concomitant ApoE4 expressed protein) associated with worse outcome than ApoE3 following TBI.   As part of our TBI research program we are exploring the molecular, neurobehavioral and neuropathological outcome after TBI in mouse models of injury, including APOE transgenic mice.

In order to evaluate differential outcomes of injury and its effects on motor skills and memory, we have optimized a series of neurobehavioral tests in mice.  The Rotarod test measures motor skill and learning via a programmable rotating bar.  Rotarod has shown the ability to distinguish between injured and uninjured mice, and has shown appropriate trends between differing levels of injury.  Morris water maze is a test of spatial memory and learning originally designed for rats but later adapted for mice.  APOE3 mice performed better than APOE4 mice in our Rotarod results, demonstrating an APOE genotype-dependent effect on motor function following TBI.  However, in the cognitive paradigm not only did we fail to detect any APOE genotype-dependent effects, we observed no significant differences in performance between injured and uninjured mice.  We therefore explored other cognitive paradigms for their ability to discriminate between injured and uninjured mice.

The Barnes maze is analogous to the Morris water maze in that it is also a test of spatial memory and learning, but because swimming is not involved it is associated with less stress than MWM typically induces in mice.  Others have shown that there is a strain-dependent effect on the ability of mice to learn the water maze task as well as the Barnes maze task.  Given that C57BL/6J mice are reported to perform better on the Barnes maze task, and this is the background strain utilized in our research, we optimized a paradigm of the Barnes maze for use in our TBI studies.  Our results show a statistically significant effect of injury on the spatial memory and learning of C57BL/6J wild type mice.  Future studies will re-examine the effect of APOE genotype on spatial memory following TBI using this test.

This research was funded by a Department of Defense award (W81XWH-07-1-0700) to Dr. Fiona Crawford and by the Roskamp Foundation

APP is Internalized After CD40 Ligation Which Increases Aβ Production

Ghania Ait-Ghezala, Jeremy Frieling, Myles Mullan, Claude-Henry Volmar, and Michael J. Mullan.

CD40, a member of the tumor necrosis factor receptor superfamily, and its cognate ligand CD40L are both elevated in the brains of Alzheimer’s disease (AD) patients compared to controls. We have shown that pharmacological or genetic interruption of CD40/CD40L interaction results in mitigation of AD-like pathology in vivo in transgenic AD mouse models, and in vitro. Recently, we showed that CD40L stimulation could increase Aβ levels, but the mechanism causing this phenomenon is not known. Here we show that CD40 ligation triggers internalization of APP and that internalization by endocytosis is associated with increased Aβ production. Furthermore, anthocyanins, which are known to impact trafficking to and from lipid rafts, impair the production of Aβ by CD40L stimulated CD40. However, anthocyanins have no effect on CD40L treatment of a neuroblastoma cell line over-expressing the C-99 APP fragment suggesting that CD40L internalization has no effect on γ-secretase. This finding is consistent with previous data suggesting that endocytosis increases BACE activity. In summary, these data suggest that a general mechanism of increased Aβ generation may be lipid raft mediated internalization of APP allowing increased BACE activity on its substrate.

Neurobehavioral profiles of two mouse models of Gulf War Illness

Laila Abdullah1, Alex Bishop1, John Phillips1, Benoit Mouzon1,2, Scott Ferguson1,2, Vani Ganapathi1, Myles Mullan1,2, Ghania Ait-Ghezala PhD1,2, Michael Mullan MD, PhD1,2 and Fiona Crawford PhD1,2

Affiliations: 1Roskamp Institute, 2040 Whitfield Ave, Sarasota, FL, 34243, 2James A. Haley VA Hospital, 13000 Bruce B. Downs Blvd, Tampa, FL, 33612.

Background: Gulf War Illness (GWI) is a multisymptom condition associated with service in the 1990-1991 Persian Gulf War conflict and affects around 250,000 US veterans. It is largely attributed to combined exposure to pyridostigmine bromide (PB) and overuse of pesticides and insect repellants.  After nearly two decades, there is still no treatment for GWI and the underlying pathologic factors associated with the observed central nervous system (CNS)-based symptoms in veterans remain unclear.  Current GWI animal models do not demonstrate the full spectrum of neurobehavioral features reported to be associated with GWI, which makes it particularly difficult to explore the efficacy of possible therapeutic options.  Therefore, we tested two different treatment paradigms in order to establish a mouse model of GWI, which exhibits motor, cognitive and anxiety-related symptoms that are observed in veterans with this illness.  Methods: For model A, a previously established treatment paradigm was used which showed pathological changes suggestive of neurodegeneration, however extensive neurobehavioral profiling was not performed. Treated C57BL6 mice received oral administration of 1.3mg/kg of PB in water, dermal application of 0.13mg/kg of permethrin (PER) and 40 mg/kg of N-N-diethyl m-toluamide 2 (DEET) in 70% ethanol and 5 minutes of restrained stress daily for 28 days, whereas control mice received vehicle for the same duration.  For model B, a new treatment paradigm was developed where CD1 mice in the treatment group were administered 2mg/kg of PB and 200 mg/kg of PER via i.p. in DMSO daily for 10 days and the control group received DMSO only.  Following treatment, neurobehavioral profiles were examined using the Rotarod test to assess motor deficits, the Open Field test for anxiety-related changes and the Morris Water Maze test to assess spatial memory.  Results: In model A, treatment was associated with significant impairment in sensorimotor function and presence of anxiety-related behavior, but there was no deficit in spatial memory.  In model B, a delayed adverse effect of treatment was observed on the outcome measures of anxiety and spatial memory, but there was no evidence of sensorimotor impairment.  Conclusion: These findings suggest that combined exposure to PB and pesticides/insect repellents may lead to CNS-based effects in mice that mimic some of the clinical symptoms observed in veterans with GWI.  Additional studies are required to determine whether all three neurobehavioral features can be produced in one mouse model and whether these changes correlate with pathological features associated with neurodegeneration.

Acknowledgment: Funding for this research is provided by a Congressionally Directed Medical Research award (GW080094) to Dr. Fiona Crawford.

Proteomic identification of plasma TBI biomarkers

Benoit Mouzon1,2, Alex Bishop1, Gogce Kayihan1,2, Ben Katz1, Scott Ferguson1,2, Jon Reed1, Venkatarajan Mathura1, Michael Mullan1,2 and Fiona Crawford1,2

1Roskamp Institute, Sarasota, Florida

2James A. Haley Veterans’ Hospital, Tampa, Florida

Traumatic Brain Injury (TBI) is a major cause of mortality and morbidity in both military and civilian populations. The current lack of prognostic biomarkers for TBI confounds treatment and management of patients and is of increasing concern as the TBI population grows.  As part of our TBI research program we are generating brain and plasma proteomic profiles from APOE3 and APOE4 transgenic mice which demonstrate relatively favorable and unfavorable outcomes respectively, following TBI.  In this study we used proteomic approaches to identify the changes in plasma protein profiles in APOE3 and APOE4 mice following severe TBI, in order to determine peripheral biomarkers associated with a poor outcome after TBI.

Using a quantitative proteomics approach (isobaric tagging for relative and absolute quantitation – iTRAQ) we have identified proteins that are significantly modulated as a function of APOE genotype, injury and the interactive term of “genotype*injury”. Analysis of modulated plasma proteins revealed significant differences in proteomic response at 24 hours, 1 month and 3 months post injury across genotypes.  From these proteomic datasets we have identified 83 proteins at the 24 hour timepoint, 170 at 1 month and 129 at 3 months post TBI. For each timepoint, the identified proteins included those whose response was dependent on injury or the injury*genotype interaction, suggesting them as potential biomarkers of injury or outcome following injury.

In pilot validation studies, using antibody-based approaches in the original plasma from these mice, we have demonstrated the validity of our approach.  These preliminary data clearly demonstrate plasma protein changes that are not only injury-dependent but also interaction-dependent. The identified proteins include biomarkers that have been previously implicated in human TBI, and their time course and relationship to neurobehavior and pathology are now to be examined in these mouse models.  Importantly these results demonstrate the presence of TBI-dependent and interaction-dependent plasma proteins at a 3 months time point, which is a considerable time post-injury in the mouse model and will potentially be of significance for combat veterans receiving assessment at extended periods post-injury.  Furthermore, our identification of clusters of related proteins indicates disturbance of particular biological modules which increases their value beyond that of solitary biomarkers.  Clinical assays for many of these proteins are already established, which will facilitate translation of our findings from mouse to human.

The biomarker panels developed from this work will aid clinicians in the determination of diagnosis, prognosis, appropriate treatment and monitoring response to treatment, all of which are urgently needed in TBI management. The next step will be to investigate these potential biomarkers in human TBI patients and those studies will begin this year with the VA patient population and our clinical collaborators.

Acknowledgement:  This research was funded by a Department of Defense award (W81XWH-07-1-0700) to Dr. Fiona Crawford.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949


April 29, 2010

Handling Unstructured Data in Biological Research and Clinical Trials

Filed under: Uncategorized — Tags: , , , , , — admin @ 10:40 am

Venkatarajan S. Mathura

Complex information that are available in a crude format make computational modeling and processing
a difficult objective in Biological and Health care research. Protocol revisions, process flexibility,
user adoptability should be considered in mind to develop an user friendly information management solution.
There is a great need to integrate data from several fields of research in a common platform to increase
process efficieny and reduce human errors. Realizing cost savings, application of knowledge mining tools on existing data and the need for data organization due to regulatory compliance, research groups and drug-discovery related industries are adopting electronic data capture and management solutions (EDC or EDM). Small scale setups still require an enterprise wide system that is both efficient, light weight, cost effective information management solutions that will be flexible to accomodate growth in the future. With the availability of field specific ontologies, controlled keywords/vocabularies, meta data management and language mapping tools, organization of unstructured data is becoming a feasible task. At the Roskamp Institute the Bioinformatics Group has developed several information management software to aid: Genomics, Proteomics, Animal Colony (Vivarium) and Clinical data management.

CliniProteus:
Clinical trials involve multi-site heterogeneous data generation with complex data input-formats and forms. The data should be captured and queried in an integrated fashion to facilitate further analysis. Electronic case-report forms (eCRF) are gaining popularity since it allows capture of clinical information in a rapid manner. We have designed and developed an XML based flexible clinical trials data management framework in .NET environment that can be used for efficient design and deployment of eCRFs to efficiently collate data and analyze information from multi-site clinical trials. The main components of our system include an XML form designer, a Patient registration eForm, reusable eForms, multiple-visit data capture and consolidated reports. A unique id is used for tracking the trial, site of occurrence, the patient and the year of recruitment.
Availability: http://www.rfdn.org/bioinfo/CTMS/ctms.html.

PWIMS 1.0: Proteomics Workflow and Information Management System

PWIMS is a software package that can systematically manage data in a proteomic laboratory setup. It is implemented in the LAMPP (Linux-Apache-MySQL-Perl/PHP) environment as a three-tier architecture. The client-tier is a web-browser that uses a thin-client HTTP to request resources and display responses to the user. The middle tier consists of an Apache web server, PHP scripting language, the Zend (PHP script) engine. The database tier uses MySQL RDBMS. Data Models and Entity-Relationships have been defined for handling data at various levels.

Some of the features of PWIMS are:

User Management: Multiple user settings, password authentication and access restriction depending on user role

Project Management: Project tracking, online availability of experiment status, experiment results, coordinators information, timeline and date records of the project.

Scheduling & Workflow Control: Tracks the workflow using unique codes for gels and target plates, controls workflow step-skipping and erroneous data entry, systematically schedules next step in the process, lists pending jobs

Data Capture: Form-based data entry, automatic mapping and transfer of large project files using FTP protocols, data can also be entered in a simple EXCEL sheet and uploaded

Data Integration & Analysis: Mass spec results are integrated to gels and projects. Protein hits can be filtered and exported for future reference or any other software, e.g., PDQuest. External links to UniProt, PUBMED, etc. are automatically provided

Data Mining & Presentation: Sequence motif search, functional keyword search and advanced queries can be specified. Results are made available for presentation and sharing.

GEMAT Genomics Experiment Management and Analysis Tool . GEMAT is an information management system designed as client-server tool for handling Affymetrix GeneChip information. It has builtin analytical tools for performing data mining and posting microarry data to endusers.

April 28, 2010

Roskamp Institute is participating in VA Research Week Activities

Filed under: Uncategorized — Tags: , , — Gogce Crynen @ 4:33 pm

Veterans Affairs is celebrating 85th year in research this week (April 26-30, 2010). One of the events is a poster session where scientists will be presenting their most recent work. We are proud to say that most of our PhD students and research assistants will be in the auditorium of the James A Haley VA Hospital in Tampa, FL to present their posters tomorrow (April 29th 2010). For more information about the VA Research Week please visit this site.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949


Roskamp Institute-LECOM collaboration

Dr. Corbin Bachmeier of the Roskamp Institute is currently investigating the drug efflux transport interactions of various antidepressants in collaboration with Dr. Gary Levin of the Lake Erie College of Osteopathic Medicine (LECOM) in Bradenton, FL.  Dr. Bachmeier and Dr. Levin are co-investigators of a grant, provided by Wyeth Pharmaceuticals, which examines the interactions of two antidepressant medications currently on the market, venlafaxine (Effexor) and desvenlafaxine (Pristiq), with the drug efflux transport proteins P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).  Previous efforts by this group found that treatment with venlafaxine in caco-2 cells, a model of intestinal absorption, induced the mRNA expression levels for P-gp.  This work is reported in the scientific journal Human Psychopharmacology: Clinical and Experimental (Ehret et al., 2007).  Their existing research aims to expound upon these findings by not only examining the impact of treatment with venlafaxine and its metabolite, desvenlafaxine, on the expression of P-gp at the protein level, but also determine their effect on BCRP protein expression levels.  In addition to testing in the caco-2 cells, this research will also evaluate the impact of these drugs on transporter expression in brain endothelial cells, which constitute the blood-brain barrier (BBB).  This research will examine the potential for drug-drug interactions with these therapies and may influence the manner in which these drugs are currently prescribed.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

April 27, 2010

High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer’s disease patients

By Abdullah L, Luis C, Paris D, Ait-ghezala G, Mouzon B, Allen E, Parrish J, Mullan MA, Ferguson S, Wood M, Crawford F, Mullan M. These findings were published in Molecular Medicine 2009 Mar-Apr;15(3-4):95-100.

Alzheimer’s disease is clinically characterized by progressive cognitive decline accompanied by the presence of amyloid plaques and neurofibrillary tangles in the brain of Alzheimer’s patients. A small protein fragment beta-amyloid (Abeta) with 42 amino acids is shown to deposit earlier in the disease process than the slightly shorter form (40 amino acid fragment).  Both species of this protein fragment are considered toxic to the brain and are shown to have an important role in causing Alzheimer’s disease.  Current research suggests that the disease process in Alzheimer’s begins long before the presence of palpable symptoms and widespread damage in the brain. Therefore, use of beta-amyloid seems promising in identification of individuals at-risk of developing Alzheimer’s disease.  Clinical studies have previously shown that blood and cerebrospinal fluid levels of Abeta may be helpful in diagnosis of Alzheimer’s disease but are influenced by factors such as presence of family history and other risk factors. The main objective of a recent study published by the scientists at the Roskamp Institute was to determine whether elevated blood Abeta levels among the first-degree relatives of patients with Alzheimer’s disease are associated with certain risk factors of cardiovascular disease that are also risk factors Alzheimer’s disease, such as hypertension.  Blood Abeta was measured in disease-free first-degree relatives of patients with Alzheimer-like dementia. Study participants were recruited as part of an ancillary study of the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT subpopulation) which was funded by the National Institutes of Health (UO1AG15477).  Examination of Abeta in this group of individuals showed that Abeta(1-40) fragment was positively associated with age and use of anti-hypertensive medications, but a negative relationship was observed in those individuals who experienced some increase in systolic blood pressure, despite being on anti-hypertensive medication.  On the other hand, the more toxic Abeta(1-42) was associated with statin use (medications used for lowering cholesterol) and with high-density lipoproteins was observed among statin nonusers. These findings suggest that high Abeta in blood samples of family history-enriched individuals may be due to enrichment of vascular risk factors and may reflect presymptomatic stage of Alzheimer’s disease.  As anti-hypertensive medications and statins are considered to be protective against Alzheimer’s disease onset, it remains to be determined whether their association with Abeta reflects mitigation of Abeta-related toxicity in the brain. Longitudinal evaluation of blood Abeta in this cohort will provide a better understanding of the significance of this association in Alzheimer’s disease etiology.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949

April 26, 2010

Journal Club: The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia

Filed under: Uncategorized — Tags: , , , — Gogce Crynen @ 11:13 am

JC Nowell Ganey will present “The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia” on Thursday (29th April 2010) at 4:00pm in Roskamp Institute. You can find the article in the following link.

The Roskamp Institute provides a full range of services for individuals with Alzheimer’s disease including diagnostic work-up and follow-up treatment, neuropsychological examination, clinical trial opportunities, and memory screening.  For more information, please call (941)752-2949

Alzheimer’s Disease Anti-Inflammatory Prevention Trial

The Roskamp Institute Memory Center is actively following a large number of subjects who participated in the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). Although earlier detection and the development of disease modifying treatment continues to be a primary focus of research and several potential compounds are under clinical trial, more prevention studies are needed.

The Roskamp Institute provides a full range of services for individuals with Alzheimer’s disease including diagnostic work-up and follow-up treatment, neuropsychological examination, clinical trial opportunities, and memory screening.  For more information, please call (941) 256-8018.

April 23, 2010

Roskamp Institute is at Facebook!

Filed under: Uncategorized — Gogce Crynen @ 3:48 pm

If you like to follow us on Facebook please follow the link. We will be posting upcoming events, peer reviewed publications, presentation and other exciting news.

Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APPSW transgenic mouse model for Alzheimer’s disease

Filed under: Uncategorized — admin @ 3:04 pm

A methodology is described for use of a 16-hole circular platform task to test spatial memory in mice. Both bright light and a fan were used to motivate mice to escape the platform surface through a single hole containing an attached escape box. For each daily trial, three correlated measures (escape latency, number of errors, and error rating) comprehensively evaluated cognitive performance. In an initial study, the ‘spatial’ nature of this task was demonstrated by the much poorer performance of non-transgenic mice when visual cues are removed. Behavioral sensitivity of the circular platform task was then shown through its ability to discern cognitive impairment in 7-month-old transgenic mice, carrying the mutant APPSW gene for early-onset Alzheimer’s disease in humans, from non-transgenic litter-mates. Since there are currently only a few tasks available to definitively test cognitive performance in mice, the circular platform task offers a versatile, multiple-measure option with numerous advantages. Particularly in view of the increasing number of genetically manipulated mouse models being produced, the circular platform task should be most useful in providing a sensitive evaluation of cognition in mice.

Characteristics of thein VitroVasoactivity of β-Amyloid Peptides

Fiona Crawford1, Zhiming Suo, Chunhong Fang and Mike Mullan

Roskamp Laboratories, Department of Psychiatry, 3515 East Fletcher Avenue, University of South Florida, Tampa, Florida, 33613

Abstract

The β-amyloid (Aβ1–40) peptide has previously been shown to enhance phenylephrine contraction of aortic ringsin vitro.We have employed a novel observation, that Aβ peptides enhance endothelin-1 (ET-1) contraction, to examine the relationship between vasoactivity and potential amyloidogenicity of Aβ peptides, the role played by free radicals and calcium in the vasoactive mechanism, and the requirement of an intact endothelial layer for enhancement of vasoactivity. Rings of rat aortae were constricted with ET-1 before and after addition of amyloid peptide and/or other compounds, and a comparison was made between post- and pretreatment contractions. In this system, vessel constriction is consistently dramatically enhanced by Aβ1–40, is enhanced less so by Aβ1–42, and is not enhanced by Aβ25–35. The endothelium isnotrequired for Aβ vasoactivity, and calcium channel blockers have a greater effect than antioxidants in blocking enhancement of vasoconstriction by Aβ peptides. In contrast to Aβ-induced cytotoxicity, Aβ-induced vasoactivity is immediate, occurs in response to low doses of freshly solubilized peptide, and appears to be inversely related to the amyloidogenic potential of the Aβ peptides. We conclude that the mechanism of Aβ vasoactivity is distinct from that of Aβ cytotoxicity. Although free radicals appear to modulate the vasoactive effects, the lack of requirement for endothelium suggests that loss of the free radical balance (between NO and O−2) may be a secondary influence on Aβ enhancement of vasoconstriction. These effects of Aβ on isolated vessels, and reported effects of Aβ in cells of the vasculature, suggest that Aβ-induced disruption of vascular tone may be a factor in the pathogenesis of cerebral amyloid angiopathy and Alzheimer’s disease. Although the mechanism of enhanced vasoconstriction is unknown, it is reasonable to propose thatin vivocontact of Aβ peptides with small cerebral vessels may increase their tendency to constrict and oppose their tendency to relax. The subclinical ischemia resulting from this would be expected to up-regulate βAPP production in and around the vasculature with further increase in Aβ formation and deposition. The disruptive and degenerative effects of such a cycle would lead to the complete destruction of cerebral vessels and consequently neuronal degeneration in the affected areas.

Author Keywords: β-amyloid; vasoactivity; Alzheimer’s disease; cerebral amyloid angiopathy; endothelin-1.

Cross Validation of the Montreal Cognitive Assessment in Community Dwelling Older Adults Residing in the Southeastern US

By Cheryl A. Luis, Andrew Keegan, and Michael Mullan

Int J Geriatr Psychiatry. 2009 Feb;24(2):197-201.

Suitable methods of earlier detection of memory changes, before the full onset of a dementia are needed.  Methods such as imaging for abnormal protein accumulation in the brain and lumbar puncture to measure abnormal proteins in cerebral spinal fluid are not likely to be useful for wide-scale use due to costs and the invasive nature of the procedure.  In this study, we examined the utility of a brief cognitive screen (the Montreal Cognitive Assessment; MoCA), compared to a widely used instrument (the Mini-Mental State Exam; MMSE) in detecting older adults living in the community experiencing significant memory decline and the early signs of dementia. One hundred and eighteen individuals, over the age of 70, participated in the project. The MoCA proved to be highly sensitive in identifying participants with memory problems.  The MMSE was ineffective in comparison. Brief screening instruments such as the MoCA provide an objective and cost-effective means of determining the need for further evaluation of memory changes in older adults at risk for dementia.

The Roskamp Institute provides a full range of services for individuals with Alzheimer’s disease including diagnostic work-up and follow-up treatment, neuropsychological examination, clinical trial opportunities, and memory screening.  For more information, please call (941) 256-8018.

September 10, 2009

Roskamp Institute Scientist Awarded a grant from the Alzheimers Association to investigate a novel therapeutic agent for the treatment of Alzheimer’s Disease.

Filed under: Uncategorized — admin @ 10:56 am

Sarasota, Fla. Dr. Daniel Paris, a senior scientist of the Roskamp Institute, was awarded an Investigator Initiated Research Grant Award from the Alzheimer’s Association to investigate the preclinical efficacy of a natural compound (celastrol) in a genetically engineered mouse model of Alzheimer’s disease.

The brain of Alzheimer’s disease patients is characterized by the accumulation of a small protein called beta-amyloid or Abeta and by the presence of intraneuronal tangle of a protein called tau. Abeta appears to be a key player in the pathology of Alzheimer’s disease and has been shown to trigger memory impairment, neuronal loss, abnormal tau protein accumulation, as well as cerebrovascular damages in various animal models of the disease. Abeta is produced by the cleavage of a larger protein precursor by two different enzymes called beta and gamma-secretase. Beta-secretase is the rate limiting enzyme in the production of Abeta and is viewed as a golden target for the treatment of Alzheimer’s disease. However despite intensive work, direct inhibitors of beta-secretase or Gamma-secretase with good drug-like properties have been extremely difficult to make. Given the difficulties being encountered by pharmaceutical industries for developing direct secretase inhibitors, Dr. Paris hypothesized that drugs which indirectly target the beta-secretase by affecting the production of the enzyme rather than by inhibiting it would be beneficial. Following the development of a screening method for identifying such drugs, Dr. Paris’ research team identified that a small molecule called celastrol is an indirect beta-secretase inhibitor that can potently oppose the production of Abeta. Celastrol is a natural compound extracted from a perennial creeping plant indigenous to a large area in southern China and known as the “Thunder of god vine”. Extracts containing celastrol have been given to Chinese patients for many years and are known to be efficient against inflammatory conditions. In the present research, Dr. Paris will determine whether celastrol holds promise as a therapeutic agent for the treatment of Alzheimer’s disease. He will further investigate whether this compound can prevent or reverse cognitive deficits, Abeta accumulation and tau pathology that affect a transgenic mouse model of Alzheimer’s disease.

Roskamp is a not-for-profit research Institute located in Sarasota, Fla., that is dedicated to understanding the causes of, and finding cures for, neuropsychiatric and neurodegenerative disorders with an emphasis on Alzheimer’s disease. The Institute’s Memory Clinic also offers comprehensive cognitive and medical assessment toward differential diagnosis of Alzheimer’s disease and offers treatments and disease management options once the diagnostic evaluation is complete.

For more information, please contact the Institute at (941) 752-2949, Roskamp’s Clinical Trials Division in Sarasota at (941) 256-8018 or visit www.RoskampInstitute.com.

Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer’s Disease.

Filed under: Uncategorized — admin @ 10:56 am

Sarasota, FL The Roskamp Institute today announced that its researchers have uncovered a new link between inflammation and Alzheimer’s disease and have identified a potential target for developing novel therapeutics for intervention in this disease. The study, led by Roskamp Institute’s Pancham Bakshi, Ph.D., is detailed in the American Chemical Society’s Chemical Biology Journal, a leading online publisher of peer-reviewed research.

It has long been known that Alzheimer’s disease is accompanied by inflammation, which both exacerbates and is caused by the underlying disease. In addition, it has long been suggested that abnormal deposits of a small protein, known as amyloid, which accumulate in the brain of those afflicted by Alzheimer’s disease, also trigger an inflammatory response. This inflammatory response is thought to be detrimental to nerve cells, eventually causing their destruction.

Recent research at the Roskamp Institute has revealed that inflammation can lead to the production of more amyloid, and researchers have found that a specific receptor on the nerve cell surface, known as CXCR2, is an interface between inflammation and new amyloid production. As specific inflammatory molecules contact CXCR2, a signal is generated which results in increased amyloid production. The presence of the abnormally occurring amyloid; therefore, contributes to its own reproduction through the inflammatory response it triggers.

“I found that by genetically knocking out CXCR2, we can reduce the amount of amyloid in various laboratory models and, by using drugs that specifically block the CXCR2 receptor, we are able to show that a decrease in production of amyloid can be achieved,” said Dr. Bakshi. “This study, which for the first time shows the early role of inflammation in AD, opens a new door for therapeutic intervention, potentially leading to the use of CXCR2 blocking agents as a way to treat both the inflammation and the amyloid production in Alzheimer’s disease.”

“Finding new classes of medications for Alzheimer’s disease is a world-wide priority,” said Michael Mullan, M.B.B.S., Ph.D., director of the Roskamp Institute. “Dr. Bakshi’s work highlights a new class of drugs that should have the benefit of both stopping inflammation and, importantly, stopping the accumulation of the pathologic amyloid. In addition to the drug Dr. Bakshi has already tested, she is making her own drugs to attack this potentially important target.”

Dr. Bakshi is currently a scientist II in the Roskamp Institute and leads the Laboratory of Chemical Biology and Drug Discovery in Neurology. Prior to the Roskamp Institute, Dr. Bakshi was a postdoctoral researcher with Dr. Michael Wolfe at Harvard Medical School, Center for Neurology from 2001-2004 and a sabbatical postdoctoral fellow at Harvard Medical School, Laboratory of Drug Discovery in Neurology with Dr. Michael Wolfe and Dr. Ross Stein from 2002-2003. Dr. Bakshi has a Ph.D. in Bioorganic Chemistry from the Center for Biochemical Technology, New Delhi, and a Master of Science in Organic Chemistry and Bachelor of Science in Chemistry from the University of Delhi, New Delhi.

The Roskamp Institute is a not-for-profit research Institute located in Manatee County and Hillsborough County, Florida, that is dedicated to understanding the causes of, and finding cures for, neuropsychiatric and neurodegenerative disorders and addictions with an emphasis on Alzheimer’s disease. The Roskamp Institute’s Memory Centers also offer comprehensive cognitive and medical assessment toward differential diagnosis of Alzheimer’s disease and offers treatments and disease management options once the diagnostic evaluation is complete.

For more information, please contact the Institute at (941) 752-2949, Roskamp’s Clinical Trials Division in Sarasota at (941) 256-8018 or visit www.RoskampInstitute.com.

Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program

Filed under: Uncategorized — Tags: , — admin @ 10:56 am

Sarasota, FL Sarasota’s Roskamp Institute (Roskamp) today announced the first enrollment of students in its pioneering three-year Ph.D. program through which students will conduct full-time laboratory research with direct mentoring from internationally-recognized scientists. Roskamp is an Affiliated Research Centre (ARC) of the United Kingdom’s Open University (OU) and was recently granted a license from the Commission for Independent Education within the Florida Department of Education to begin this program.

“Roskamp has always played a significant role in training and mentoring top quality students, and we are delighted to now have a formal degree-awarding program,” said Dr. Fiona Crawford, associate director of Roskamp. “With the enrollment of our first successful applicants, we look forward to further enhancing the Institute and its many partners and collaborators in Florida, as well as the local developing biotechnology community.”

“Our Ph.D. program brings the opportunity for postgraduate research students to participate in a one-of-a-kind program that will expose them to a world-class research facility,” said Dr. Michael Mullan, director of Roskamp. “They will work side-by-side with exceptional scientists, perform hands-on, laboratory-based research and gain the practical knowledge necessary to succeed in their area of research, and emerge as fully operational professionals.”

The Institute has enrolled three students in its Ph.D. program, which will expose them to Roskamp’s state-of-the-art technology and will allow them to gain knowledge of the Institute’s key divisions, including chemistry, proteomics and molecular biology. The first class of students in the program will pursue dissertation research on Gulf War Syndrome, Traumatic Brain Injury and Alzheimer’s disease.

Laila Abdullah, M.S., is a graduate of the University of South Florida with a Bachelor of Science in Biology and a master’s in Epidemiology. Abdullah is studying the biological cause of the chronic and complex health problems that Persian Gulf War veterans experience compared to other veterans, using both standard molecular biology and advanced proteomic technology.

Scott Ferguson is a graduate of the University of Central Florida with a Bachelor of Science in Micro/Molecular Biology. Ferguson is studying how brain proteins respond to traumatic injury in order to identify new ways to treat the long-term consequences of these injuries which are of such high prevalence in the military and civilian populations.

Nowell Ganey, who is a graduate of the University of Florida with a Bachelor of Science in Nutritional Science, is building on the seminal work of lead Institute scientists by exploring the mechanisms linking vascular factors to the development of Alzheimer’s disease.

OU has a 110 acre campus in Milton Keynes, England, and is also a distance learning university and the leading eLearning University in the U.K. for its quality of teaching. With the addition of Roskamp, there are 24 OU ARCs around the world. In addition to the research degree programs, OU is a very large teaching university. More than 2 million students have studied at OU since its inception in 1971. The OU is accredited by the U.S. Middle States Commission on Higher Education.

Roskamp is a not-for-profit research Institute located in Sarasota, Fla., that is dedicated to understanding the causes of, and finding cures for, neuropsychiatric and neurodegenerative disorders with an emphasis on Alzheimer’s disease. The Institute’s Memory Clinic also offers comprehensive cognitive and medical assessment toward differential diagnosis of Alzheimer’s disease and offers treatments and disease management options once the diagnostic evaluation is complete.

For more information, please contact the Institute at (941) 752-2949, Roskamp’s Clinical Trials Division in Sarasota at (941) 256-8018 or visit www.RoskampInstitute.com.

Southeast High School’s Roskamp Institute project placed first in Florida and fifth in National Technology Students Association finals

Filed under: Uncategorized — admin @ 10:55 am

Sarasota, FL Roskamp Institute was the focus of Southeast High Technology Student Association (TSA) team project in the Medical Technology category which was awarded fifth place in the Nation at the 31ST Annual TSA National Conference in Denver, Colorado June 28 – July 2 after wining first place in the State of Florida competition held in Orlando on March 3rd 2009 . The team fromSoutheast attended the National finals representing the State of Florida and holds the distinction of being Florida’s Most Outstanding TSA High School.

The Team’s project highlighted some of the cutting edge research being carried out at the Roskamp Institute. The TSA team members from Southeast High are Maya Meredith, Andres Romero, Rachel Metras, Lor Gregor, Diego Corzo, John Nguyen, Marissa Bressi. As well, the team won first place in Florida for another Roskamp-assisted project in the Scientific Visualization category. Southeast High School is located in Bradenton, Florida and is an International Baccalaureate Diploma School.

Please click here to see video of this award wining work by the Team from Southeast High.

Roskamp is a not-for-profit research Institute located in Sarasota, Fla., that is dedicated to understanding the causes of, and finding cures for, neuropsychiatric and neurodegenerative disorders with an emphasis on Alzheimer’s disease. The Institute’s Memory Clinic also offers comprehensive cognitive and medical assessment toward differential diagnosis of Alzheimer’s disease and offers treatments and disease management options once the diagnostic evaluation is complete.

For more information, please contact the Institute at (941) 752-2949, Roskamp’s Clinical Trials Division in Sarasota at (941) 256-8018 or visit www.RoskampInstitute.com.
Videos

Local Researchers at Roskamp Institute to Test Investigational Gammaglobulin Treatment for Alzheimer’s Disease

Filed under: Uncategorized — admin @ 10:50 am

This summer, researchers from Roskamp Institute in Sarasota, FL, will begin testing an investigational approach to slowing down the progression of Alzheimer’s disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin. IGIV is currently used to treat primary immunodeficiency disorders but is not currently approved for treating AD, which is one of the leading causes of dementia in the elderly.

Initial research in experimental models and patients suggests that immunotherapy targeting beta amyloid (the protein that forms the core of plaques in the brain) may provide an effective way to treat AD. Antibodies that bind to beta amyloid are present in IGIV, which is made from the blood of several thousand healthy adults. This effort seeks the public’s participation in testing IGIV in a major clinical trial that is jointly funded by the National Institute on Aging and Baxter International Inc.

One of the hallmarks of AD pathology is an abundance of beta-amyloid deposits in the brain. While it is not yet known if beta amyloid plaques cause AD or are a byproduct of the disease, scientists are interested in finding ways to reduce the toxic effects of beta amyloid on the brain. Antibodies against beta amyloid may do so by binding to toxic forms of beta amyloid, thereby neutralizing them and/or promoting their elimination.

“We are investigating whether IGIV, which contains naturally occurring human anti-amyloid antibodies, will defend the brain of AD patients against the damaging effects of beta amyloid. If it does, giving IGIV to patients with mild to moderate Alzheimer’s may potentially slow the rate of progression of the disease,” says Dr. Andrew Keegan, the principal investigator for the study at Roskamp Institute.

“In our initial studies in AD patients, IGIV provided cognitive benefits, improved brain metabolism and reduced beta amyloid levels in the spinal fluid,” says Norman Relkin, M.D., Project Director and Director of the Weill Cornell Alzheimer’s Disease and Memory Disorders Program. In a Phase II trial at Weill Cornell, Dr. Relkin reported that participants undergoing several months of continuous IGIV therapy also demonstrated improvement in their activities of daily living. He added, “These findings, as well as IGIV’s established record of use for treating other diseases, provide a strong rationale for further study in AD patients on a larger scale.”

The GAP (Gammaglobulin Alzheimer’s Partnership) Study will examine the safety, effectiveness and tolerability of IGIV in patients with mild to moderate AD. GAP is recruiting 360 participants at 36 sites nationwide. This large Phase III clinical trial expands on earlier testing, is one of two Phase III trials, and is part of the final phase in studying IGIV as a potential treatment for AD before seeking regulatory approval.

The GAP trial is a double-blind, placebo-controlled study in which two-thirds of participants will receive IGIV and one-third will receive placebo. It will last up to 82 weeks. Sites are looking for study volunteers who fit the following criteria:

* Male or female, 50-89 years old
* Have been diagnosed with probable mild to moderate Alzheimer’s disease
* Have a study partner (spouse, child, sibling or friend) in contact with the participant 10 hours/week or more

The trial is being conducted by the Alzheimer’s Disease Cooperative Study (ADCS), a nationwide consortium of research centers and clinics coordinated by the University of California at San Diego and directed by Paul Aisen, M.D.

“As many as five million Americans may be afflicted now and with the numbers growing rapidly, ADCS clinical trials such as the GAP study are essential to finding new and more effective treatments for Alzheimer’s disease,” Aisen commented.

The ADCS is primarily supported by the National Institute on Aging (NIA), part of the National Institutes of Health. The GAP study is jointly funded by Baxter International Inc. and the NIA. For further information on the trial, please go to: http://www.adcs.org/Studies/IGIV.aspx

For more information on this study and Alzheimer’s disease, please visit the Alzheimer’s Disease Education and Referral Center website: http://www.alzheimers.org/clinicaltrials/fullrec.asp?PrimaryKey=282

Roskamp is a not-for-profit research Institute located in Sarasota, Fla., that is dedicated to understanding the causes of, and finding cures for, neuropsychiatric and neurodegenerative disorders with an emphasis on Alzheimer’s disease. The Institute’s Memory Clinic also offers comprehensive cognitive and medical assessment toward differential diagnosis of Alzheimer’s disease and offers treatments and disease management options once the diagnostic evaluation is complete.

Contact:
Dr. Andrew Keegan Jeffree Itrich
Roskamp Institute Alzheimer’s Disease Cooperative Study
email: rclinic @ rfdn.org email:jitrich @ ucsd.edu
Phone: (941)256-8018 Phone:(858)622-5827
www.RoskampInstitute.com www.adcs.org

For more information, please contact the Institute at (941) 752-2949, Roskamp’s Clinical Trials Division in Sarasota at (941) 256-8018 or visit www.RoskampInstitute.com.

World Alzheimer’s Day: Leaders Call for Early Diagnosis and Aggressive Research

Filed under: Uncategorized — Tags: , , — admin @ 9:59 am

Alzheimer’s disease carries an annual price tag of $148 billion dollars, not to mention the personal toll that it takes on the over 5.3 million patients and their families.

More than 5.3 million Americans are living with Alzheimer’s, and every 72 seconds someone in America develops the disease. According to the Alzheimer’s Association, by mid-century someone will develop Alzheimer’s every 33 seconds, and there will be nearly a million new cases per year.

“With the country facing unprecedented economic challenges and a rapidly aging baby boomer population, now is the time to address the burgeoning Alzheimer’s crisis that triples healthcare costs for Americans aged 65 and over,” said Harry Johns, Alzheimer’s Association CEO.

Alzheimer’s disease is a neurodegenerative disorder characterized by progressive loss of memory and cognitive function. It destroys brain cells, causing problems with memory, thinking, and behavior that are severe enough to affect everyday life.

Experts believe that early detection of Alzheimer’s disease and early intervention with improved therapies provides the greatest opportunity to modify or halt disease progression. Most current therapies for Alzheimer’s treat the symptoms associated with it and not the disease itself.

“There is a rich, diverse variety of treatment possibilities for Alzheimer’s that scientists are exploring, offering great hope that drugs that may slow or even reverse disease progression could be on the horizon—saving millions of dollars in public health programs,” said Ronald Petersen, M.D., Ph.D, Alzheimer’s Association Medical Scientific Advisory Council Chair. On World Alzheimer’s Day, we renew our commitment to early diagnosis and aggressive Alzheimer’s research in order to improve the health outcomes for people living with this disease.

Dr. Andrew Keegan and other local physicians are currently researching potential new treatments for Alzheimer’s patients that target causes of the disease, such as amyloid plaques in the brain. The buildup of these plaques is thought to cause Alzheimer’s disease. Some of these investigational drugs use antibodies, or immune system proteins, to dissolve the plaques.

“There are too many lives, too little time, and too much at stake for anything less than an aggressive plan to address the threat of this disease,” Johns said.

Roskamp is a not-for-profit research Institute located in Sarasota, Fla., that is dedicated to understanding the causes of, and finding cures for, neuropsychiatric and neurodegenerative disorders with an emphasis on Alzheimer’s disease. The Institute’s Memory Clinic also offers comprehensive cognitive and medical assessment toward differential diagnosis of Alzheimer’s disease and offers treatments and disease management options once the diagnostic evaluation is complete.

Contact:
Dr. Andrew Keegan
Roskamp Institute
email: rclinic @ rfdn.org
Phone: (941)256-8018
www.RoskampInstitute.com

For more information, please contact the Institute at (941) 752-2949, Roskamp’s Clinical Trials Division in Sarasota at (941) 256-8018 or visit www.RoskampInstitute.com.

August 11, 2009

Dementia in Older Women

Filed under: Uncategorized — Tags: , , — admin @ 1:13 pm

A recent paper published in the Journal Neurology, which analyzed over 900 people, suggests that almost half of all women in their nineties are suffering from dementia. The study carried out in California is one of a few looking specifically at the rates of dementia in the very old. However, given our increased life expectancies, the over ninety group is growing rapidly in many populations, including that of the United States. Importantly, there seems to be a sex difference in the risk for Alzheimer’s or dementia in general over the age of ninety.

In men, for instance, although there was an increase in the likelihood of having dementia over the age of ninety, it did not increase as much as it did in women. In women, the likelihood of having dementia doubled every five years after the age of ninety. Previous studies have suggested that the risk for dementia is higher in women than it is in men. But other studies have disputed this. This present study seems to confirm that the risk for women is greater than men, at least after the age of ninety years.

Therefore, if you divide dementia populations by sex over the age of ninety, about 45% of women will have dementia compared to 28% of men. Importantly the study also suggested that women who had used their brains (intellect) more throughout life and had achieved higher education, were much less likely to develop dementia than those who had not.

Understanding why women in this age group might be at higher risk will take additional studies. But it is known, for instance, that women are more likely than men to develop stroke and heart disease as they age. Both of these are independent risk factors for dementia and exacerbate Alzheimer’s symptoms.

Researchers at the Roskamp Institute are interested in finding new treatments for Alzheimer’s disease and clues from sex differences that confer different risks for Alzheimer’s are important because they may point to more treatment strategies.

Researchers have, for instance, speculated that estrogen is a protective factor for Alzheimer’s disease, but proactive treatment with estrogen has not been shown to be preventative in clinical trials. In the present study, the idea that vascular risk factors (which are more prevalent in women as they age) are contributory to Alzheimer’s is consistent with much of the work of Roskamp Institute scientists showing that in the presence of amyloid, damage to the vasculature is heightened and the consequences of vascular damage has greater impact on the brain in the presence of early Alzheimer’s disease than in normal individuals. These and other clues are leading Roskamp Institute scientists towards new treatments for the disease, some of which should be entering clinical trials in 2008.

Alzheimer’s and Blood Pressure

Filed under: Uncategorized — admin @ 1:13 pm

The relationship between blood pressure and Alzheimer’s disease is complex. However, we do know that blood pressure raised in mid-life (hypertension) is a risk for the development of Alzheimer’s disease later on. Uncontrolled hypertension is a risk for dementia in general. In fact, stroke related dementias are primarily caused by either clotting or small bleeds in the brain. Hypertension can lead to bleeding, primarily in the brain, but can also damage the heart triggering the release of small clots that lodge in the brain, thus depriving the nerve cells (neurons) of oxygen supply.

It remains unclear to scientists why hypertension is a risk for Alzheimer’s disease, but we do know that in spontaneously hypertensive rats, there is a tendency to accumulate some of the pathology of Alzheimer’s disease.

In 1996, researchers at the Roskamp Institute discovered that the causative protein in Alzheimer’s (the amyloid protein) has a drastic effect on blood vessels. The effect is to increase the propensity of blood vessels to constrict. Subsequently, others show that after a small stroke (when blood vessels close down temporarily) the presence of amyloid tends to keep the blood vessels closed. It is assumed that the consequence of reduced blood flow to the brain, secondary to closed blood vessels, causes deprivation of oxygen and glucose to the neurons, thus causing more damage in a brain with high amyloid levels than one with not.

Translated into clinical terms, this means that the effect of a small stroke on somebody who is in the early stages of Alzheimer’s can be more devastating than somebody who is not. In fact, a study of nuns who were asked to complete mental state questionnaires in life and who subsequently died has revealed an important interaction between small strokes and the clinical signs of Alzheimer’s. Even though some nuns had amyloid deposits in their brain, they did not exhibit the symptoms of amyloid in life. Those nuns that had amyloid deposits but did exhibit the clinical symptoms of Alzheimer’s in life also had multiple small strokes.

Thus, damage to the blood vessels in the presence of amyloid is more devastating than if amyloid is absent. Hypertension tends to damage blood vessels throughout the body, but it is only in the brain that amyloid accumulates and can contribute to poor recovery after vascular injury.

What does this mean for patients treated at the Roskamp Institute? Patients are advised to take particular care to have their blood pressure and cardiovascular status monitored. High lipid or triglyceride levels can contribute to cerebrovascular (brain/blood vessel) damage and uncontrolled or poorly monitored high hypertension can also be highly detrimental. In addition, we know that other cardiac problems, such as arrhythmias can contribute to cerebrovascular damage, as mentioned, by throwing off small clots.

As we await effective treatments to combat Alzheimer’s directly, we need to ensure that we control other disorders which can contribute significantly to rapid declines in mental status. Interestingly, some antihypertensives seem to be able to control the risk for Alzheimer’s disease as well as controlling blood pressure.

Researchers at the Roskamp Institute have clearly shown that this does not apply to all antihypertensives and they are investigating why some are able to regulate both blood pressure and can reduce the incidence of Alzheimer’s disease while others cannot. This is an important area of research and clearly one that holds out hope for Alzheimer’s sufferers as the search for new treatments continues.

What do the names of Barack Obama, Hillary Clinton, and John McCain have to do with Alzheimer’s disease?

Filed under: Uncategorized — admin @ 1:12 pm

Alzheimer’s disease is a neurodegenerative disorder (i.e., one which attacks neurons in the brain) which robs us of our memories, language, reasoning and thought. However, the clinical picture of Alzheimer’s has a very distinctive pattern which distinguishes it from other forms of dementia (dementia is a general term which simply means the loss of memory, some other mental function, and the loss of normal social functioning). In Alzheimer’s disease, the early signs are almost invariably the same and include loss of memory for recently presented information.

What does this mean practically? It means that someone in the early stages of Alzheimer’s will not remember information presented to them a short time ago. For instance, if somebody receives a phone call, a few minutes later they may not remember who it was who called. Similarly, if they set out for the grocery store, once they arrive there they may not remember what it is they set out for.

Today, we are so used to receiving news all the time from our computers, our televisions, radios, and mobile phones that we don’t realize that we are being presented with new information all the time. The Alzheimer’s sufferer is at a particularly grave disadvantage in this situation. Current events may escape their memory stores and a good test of whether someone may be suffering from the disorder or not is whether they can remember information that appears as news on television or other ways. So, for instance, knowing the big events in the campaign for the US presidential election will be registered by most of us and remembered. The Alzheimer’s sufferer may not know that Hillary Clinton has dropped out of the race nor that Barack Obama has been nominated. Knowledge of these events, which most of us take for granted are lost to the Alzheimer’s sufferer and thus monitoring our loved ones and friends for signs that they are not aware of current events may help us to detect early signs of the disease. Concern that somebody may not be acquiring new information should be a trigger to have them evaluated in a memory disorder clinic.

The Roskamp Institute has two such clinics – one in Tampa and one in Sarasota, Florida and they offer full evaluations for Alzheimer’s and other causes of memory loss.

Double Amyloid Causes Memory Loss

Filed under: Uncategorized — admin @ 1:11 pm

A recent paper (June 22nd from scientists from Harvard University and Trinity College, Dublin) has shown that the amyloid protein is most toxic to memory when it appears in a double form. The researchers extracted the amyloid protein (the small protein that has long thought to be the cause of Alzheimer’s) from the brains of Alzheimer’s disease victims and when the proteins were injected into rats, they noted that, depending on the specific form of amyloid, memory impairment occurred.

Alzheimer, himself, saw the accumulation of amyloid protein in what are now know as plaques, but these accumulations of amyloid represent many, many single amyloid molecules aggregated together.

The researchers found that this highly aggregated form of amyloid was not injurious to memory. However, when the amyloid protein occurred in just a doublet, (i.e., two molecules of amyloid stuck together) then it was in its most toxic form. Single amyloid (which we all produce for much of the time) was harmless to memory. These findings are important because the doublet form of amyloid is soluble and therefore can travel freely throughout the brain. These findings also suggest that the aggregated form that is visible to the eye under the microscope is not the most important form for researchers to prevent.

These findings are of particular interest to researchers at the Roskamp Institute, who showed in 1996 that soluble forms of amyloid could be toxic to blood vessels, increasing the likelihood that they would constrict. This is a particularly bad thing, especially after stroke, and it raised the possibility at that time that the soluble forms of Aß of amyloid might be more important than the aggregated forms.

These new findings also suggest that treatments aimed at lowering the amount of the amyloid doublet, might be those that are most effective in the disease. The new vaccine treatment, for instance, aimed at lowering the amount of amyloid by soaking up the amyloid with an antibody, might be effective at lowering these amyloid doublets. Other drugs that are coming on-line for the treatment of Alzheimer’s also targeted at the amyloid protein will now, no doubt, be examined to see whether they can lower the amount of the amyloid doublet.

Researchers at the Roskamp Institute are dedicated to finding new treatments and cures for Alzheimer’s disease. They were among the first in the world to show that the amyloid protein was most likely central to the disease process. This theory is now being tested in clinical studies throughout the world with exciting recent results suggesting that, indeed, the removal of amyloid might be an effective treatment for the disease (see recent reports on Elan Pharmaceuticals).

First Critical Clinical Tests of the Amyloid Theory of Alzheimer’s Disease

Filed under: Uncategorized — admin @ 1:11 pm

In 1991, researchers currently at the Roskamp Institute published a paper in the highly prestigious Nature journal entitled “Early Onset Alzheimer’s Disease Caused by Mutations of the Amyloid Gene”. This and related findings were historic milestones in the understanding of the causes of Alzheimer’s disease. Today, seventeen years later, Roskamp Institute researchers are delighted to hear that Elan, one of the largest pharmaceutical companies, is having success with an approach which targets the amyloid protein.

The early findings by Roskamp researchers placed amyloid at center stage as the cause of the disease. Now Elan’s vaccine, which is targeted to soak up the amyloid protein, may be a verification that reducing amyloid accumulation is a way to tackle the disease. Although some researchers remain skeptical of the validity of this approach, the early results from Elan’s Phase II study, published this week (June 17) indicate that reducing amyloid levels with the anti-amyloid vaccine has slowed the rate of progression of the disease in some patients. Interestingly, the vaccine approach has been helpful in cases of the disease that do not have a high genetic risk loading. Although there was a hint that all cases of Alzheimer’s (even those with high genetic loading might benefit from the vaccine), there was not a statistically significant difference between placebo group and those individuals that carry an APOE4 gene. This gene is known to increase the likelihood of developing Alzheimer’s early in life and may represent a particularly aggressive form of the disorder. Nevertheless, the fact that there were trends in a treatment improvement in the high risk group and statistically significant improvement in income in the low genetic risk group, strongly suggest that targeting amyloid will be a therapeutically useful strategy.

For Roskamp Institute researchers the new data from Elan is very important as Roskamp Institute researchers have developed drugs that do the same thing as the vaccine, i.e., lower the accumulation of amyloid levels. One of those drugs is in clinical trials already in Europe and trials are set to begin in the US pending FDA approval.

For Alzheimer’s sufferers and Alzhiemer’s researchers alike, the news from Elan is very hopeful.

Older Posts »

Powered by WordPress